Arginase inhibitors and methods of use thereof

Potent arginase inhibitors address the immunosuppressive tumor microenvironment by increasing L-arginine levels, reactivating immune responses against cancer cells, and inhibiting cancer progression.

JP7579324B2Active Publication Date: 2024-11-07ASTRAZENECA AB
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022503946
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-23
Filing Date
2020-07-22
Publication Date
2024-11-07
Estimated Expiration
2040-07-22

AI Technical Summary

Technical Problem

Cancer cells employ immunosuppressive mechanisms, such as increased arginase levels, to evade the immune system by decreasing L-arginine levels in the tumor microenvironment, leading to immunosuppression and impaired T cell responsiveness.

Method used

Development of potent and selective arginase inhibitors, represented by compounds of formulas (I), (Ia), (II), (III), (IV), or Table 1, or their pharmaceutically acceptable salts, to inhibit arginase activity and reactivate anti-cancer immunity.

Benefits of technology

The arginase inhibitors effectively reverse immunosuppression by increasing L-arginine levels, enhancing T cell proliferation and immune responsiveness, thereby potentially slowing or inhibiting cancer growth and progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579324000001
    Figure 0007579324000001
  • Figure 0007579324000002
    Figure 0007579324000002
  • Figure 0007579324000003
    Figure 0007579324000003
Patent Text Reader

Abstract

Disclosed are compounds of formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing same, and methods of using same to treat cancer or respiratory inflammatory diseases, wherein: [Formula 1] TIFF2022541592000080.tif29160 formula, R 1 represents hydrogen, -CH3 and -(C=O)CH(R 1a )NH2; R 1a is C1-C4 alkyl; Y is -(CH2) n - or -(C=O)-; n is an integer selected from 1 and 2; R 2 is hydrogen, -CH3 and -(C=X)R 4 and R 3 is hydrogen or -CH3; or R 2 and R 3 are linked together with the nitrogen to which they are attached to form a 6-membered heterocycle; X is NH or O; R 4 is -CH3 or -[CH(R 4a )] m NH2; m is an integer selected from 0 or 1; and R 4a is hydrogen or C1-C6 alkyl.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] Arginase is a manganese metalloenzyme that catalyzes the conversion of L-arginine to urea and L-ornithine. Two isoforms exist: arginase 1 is a cytosolic enzyme found primarily in hepatocytes that plays a critical role in the removal of ammonia via urea synthesis, and arginase 2 is a mitochondrial enzyme highly expressed in the kidney that is involved in the production of ornithine, a precursor of polyamines and proline that are important for cell proliferation and collagen production, respectively.

[0002] L-arginine is not an essential amino acid in healthy adults because it can be provided through protein turnover, but under various physiological and pathological conditions (e.g., pregnancy, autoimmune disease, cancer), the expression and secretion of arginase increases, resulting in a decrease in L-arginine levels. In particular, immune cells are sensitive to the decrease in L-arginine levels. When T cells face a low L-arginine microenvironment, they have a reduced proliferation rate and a reduced expression of CD3ζ chain, IFNγ, and lytic enzymes, impairing T cell responsiveness. Dendritic cells respond to low L-arginine conditions by reducing their antigen-presenting capacity, and natural killer cells reduce both proliferation and expression of lytic enzymes.

[0003] Tumors evade the immune system using multiple immunosuppressive mechanisms, including the depletion of L-arginine by increasing circulating arginase levels, increased expression and secretion of arginase by tumor cells, and recruitment of myeloid-derived suppressor cells that express and secrete arginase. Together, these lead to a depletion of L-arginine in the tumor microenvironment and an immunosuppressive phenotype. Summary of the Invention [Problem to be solved by the invention]

[0004] Pharmacological inhibition of arginase activity has been shown to reverse low L-arginine-induced immunosuppression in animal models. Thus, there is a need for potent and selective arginase inhibitors that can reverse immunosuppression and reactivate anti-cancer immunity in patients, either as single agents or in combination with treatments that reverse additional immunosuppressive mechanisms. [Means for solving the problem]

[0005] In some embodiments, disclosed is a compound of formula (I): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, R 1 is hydrogen, -CH3, and -(C=O)CH(R 1a )NH2; R 1a is C1-C4 alkyl; Y is -(CH2) n - or -(C=O)-; n is an integer selected from 1 and 2; R 2 is hydrogen, -CH3, and -(C=X)R 4 and R 3 is hydrogen or -CH3; or R 2 and R 3 are linked together with the nitrogen to which they are attached to form a nitrogen-containing six-membered heterocycle; X is NH or O; R 4 is -CH3 or -[CH(R 4a )] m NH2; m is an integer selected from 0 or 1; and R 4a is hydrogen or C1-C4 alkyl; or a pharma- ceutically acceptable salt thereof.

[0006] In some embodiments, disclosed is a compound of formula (II): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, R 11 is hydrogen, -CH3, and [ka] wherein * indicates (S) stereochemistry; Y 1 is -(CH2) p - or -(C=O)-; p is an integer selected from 1 and 2; R 11a is C1-C4 alkyl; R 12 is hydrogen, -CH3, and -(C=X 1 )R 14 and R 13 is hydrogen or -CH3; or R 12 and R 13 are linked together with the nitrogen to which they are attached to form a nitrogen-containing six-membered heterocycle; X 1 is NH or O; R 14 is -CH3 or [ka] where * indicates (S) stereochemistry; R 14a is C1-C4 alkyl; and q is an integer selected from 0 and 1; or a pharma- ceutically acceptable salt thereof.

[0007] In some embodiments, disclosed is a compound of formula (III): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, R 22 is hydrogen or [ka] where * indicates (S) stereochemistry; and R 24a is C1-C4 alkyl; or a pharma- ceutically acceptable salt thereof.

[0008] In some embodiments, disclosed is a compound of formula (IV): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, R 11 teeth, [ka] where * indicates (S) stereochemistry; and R 11a is C1-C4 alkyl; or a pharma- ceutically acceptable salt thereof.

[0009] In some embodiments, disclosed is a compound of Table 1, or a pharma- ceutically acceptable salt thereof.

[0010] In some embodiments, disclosed is a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

[0011] In some embodiments, disclosed is a method of treating cancer comprising administering a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof.

[0012] In some embodiments, disclosed is a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, for treating cancer.

[0013] In some embodiments, disclosed is the use of a compound of (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cancer.

[0014] In some embodiments, disclosed is a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, for use in treating cancer.

[0015] In some embodiments, disclosed is a method of treating a respiratory inflammatory disease comprising administering a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof.

[0016] In some embodiments, disclosed is a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, for treating a respiratory inflammatory disease.

[0017] In some embodiments, disclosed is the use of a compound of (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for use in treating a respiratory inflammatory disease.

[0018] In some embodiments, disclosed is a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, for use in treating a respiratory inflammatory disease.

[0019] In some embodiments, the respiratory inflammatory disease is chronic obstructive pulmonary disease (COPD) or asthma. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] In some embodiments, disclosed is a compound of formula (I): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, R 1 is hydrogen, -CH3, and -(C=O)CH(R 1a )NH2; R 1a is C1-C4 alkyl; Y is -(CH2) n - or -(C=O)-; n is an integer selected from 1 and 2; R 2 is hydrogen, -CH3, and -(C=X)R 4 and R 3 is hydrogen or -CH3; or R 2 and R 3 are linked together with the nitrogen to which they are attached to form a nitrogen-containing six-membered heterocycle; X is NH or O; R 4 is -CH3 or -[CH(R 4a )] m NH2; m is an integer selected from 0 or 1; and R 4a is hydrogen or C1-C4 alkyl; or a pharma- ceutically acceptable salt thereof.

[0021] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n - n is 1, R 2 is hydrogen, and R 3 is hydrogen.

[0022] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n - n is 1, R 2 and R 3 are linked together with the nitrogen to which they are attached to form a nitrogen-containing 6-membered heterocycle. In some embodiments, the nitrogen-containing 6-membered heterocycle is a morpholinyl ring. In some embodiments, the nitrogen-containing 6-membered heterocycle is a piperidinyl ring.

[0023] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n - n is 1, R 2 is -CH3, and R 3 is hydrogen.

[0024] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n n is 1 and R 2 is -CH3, and R 3 is -CH3.

[0025] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n - n is 1, R 2 is -(C=X)R 4 and R 3 is hydrogen, X is NH, and R 4 is [CH(R4a )] m NH2 and m is O.

[0026] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is [CH(R 4a )] m NH2 and m is O.

[0027] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is -[CH(R 4a )] m NH2, m is 1, and R 4a is a C alkyl (e.g., isopropyl).

[0028] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 m and R 3 is hydrogen, X is O, and R 4 is -[CH(R 4a )] m NH2, m is 1, and R 4a is a C2 alkyl (e.g., ethyl).

[0029] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is -[CH(R 4a )] m NH2, m is 1, and R 4a is C alkyl (e.g., methyl).

[0030] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is -CH3.

[0031] In some embodiments, in the compound of Formula (I), R 1 is -CH3 and Y is -(CH2) n- where n is 1 and R 2 is hydrogen, and R 3 is hydrogen.

[0032] In some embodiments, in the compound of Formula (I), R 1 is -(C=O)CH(R 1a )NH2, R 1a is C alkyl (e.g., isopropyl) and R is -(CH) n- where n is 1 and R 2 is hydrogen, and R 3 is hydrogen.

[0033] In some embodiments, in the compound of Formula (I), R 1 is -(C=O)CH(R 1a )NH2, R 1a is C1 alkyl (e.g., methyl) and R is -(CH2) n- where n is 1 and R 2 is hydrogen, and R 3 is hydrogen.

[0034] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n- where n is 2 and R 2 is hydrogen, and R 3 is hydrogen.

[0035] In some embodiments, in the compound of Formula (I), R 1 is hydrogen, Y is -(C=O), and R 2 is hydrogen, and R 3 is hydrogen.

[0036] In some embodiments, in the compound of Formula (I), R 1 is hydrogen, Y is -(C=O), and R 2 is -CH3, and R 3 is hydrogen.

[0037] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is -[CH(R 4a )] m NH2, m is 1, and R 4a is a C4 alkyl (e.g., isobutyl).

[0038] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is -[CH(R 4a )] m NH2, m is 1, and R4a is a C4 alkyl (e.g., tert-butyl).

[0039] In some embodiments, in the compound of Formula (I), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is -[CH(R 4a )] m NH2, m is 1, and R 4a is hydrogen.

[0040] In some embodiments, the compound of formula (I), or a pharma- ceutically acceptable salt thereof, has formula (Ia): [ka] It is a compound of the formula:

[0041] In some embodiments, in the compound of Formula (Ia), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is hydrogen, and R 3 is hydrogen.

[0042] In some embodiments, in the compound of Formula (Ia), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 and R 3 are linked together with the nitrogen to which they are attached to form a nitrogen-containing 6-membered heterocycle. In some embodiments, the nitrogen-containing 6-membered heterocycle is a morpholinyl ring. In some embodiments, the nitrogen-containing 6-membered heterocycle is a piperidinyl ring.

[0043] In some embodiments, in the compound of Formula (Ia), R 1 is hydrogen and Y is -(CH2) n-where n is 1 and R 2 is -CH3, and R 3 is hydrogen.

[0044] In some embodiments, in the compound of Formula (Ia), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -CH3, and R 3 is -CH3.

[0045] In some embodiments, in the compound of Formula (Ia), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is NH, and R 4 is [CH(R 4a )] m NH2 and m is O.

[0046] In some embodiments, in the compound of Formula (Ia), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is [CH(R 4a )] m NH2 and m is O.

[0047] In some embodiments, in the compound of Formula (Ia), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is -[CH(R 4a )] m NH2, m is 1, and R4a is a C alkyl (e.g., isopropyl).

[0048] In some embodiments, in the compound of Formula (Ia), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 m and R 3 is hydrogen, X is O, and R 4 is -[CH(R 4a )] m NH2, m is 1, and R 4a is a C2 alkyl (e.g., ethyl).

[0049] In some embodiments, in the compound of Formula (Ia), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is -[CH(R 4a )] m NH2, m is 1, and R 4a is C alkyl (e.g., methyl).

[0050] In some embodiments, in the compound of Formula (Ia), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is -CH3.

[0051] In some embodiments, in the compound of Formula (Ia), R 1 is -CH3 and Y is -(CH2) n- where n is 1 and R 2 is hydrogen, and R 3 is hydrogen.

[0052] In some embodiments, in the compound of Formula (Ia), R 1 is -(C=O)CH(R 1a )NH2, R 1a is C alkyl (e.g., isopropyl) and R is -(CH) n- where n is 1 and R 2 is hydrogen, and R 3 is hydrogen.

[0053] In some embodiments, in the compound of Formula (Ia), R 1 is -(C=O)CH(R 1a )NH2, R 1a is C1 alkyl (e.g., methyl) and R is -(CH2) n- where n is 1 and R 2 is hydrogen, and R 3 is hydrogen.

[0054] In some embodiments, in the compound of Formula (Ia), R 1 is hydrogen and Y is -(CH2) n- where n is 2 and R 2 is hydrogen, and R 3 is hydrogen.

[0055] In some embodiments, in the compound of Formula (Ia), R 1 is hydrogen, Y is -(C=O), and R 2 and R 3 is hydrogen.

[0056] In some embodiments, in the compound of Formula (Ia), R 1 is hydrogen, Y is -(C=O), and R 2 is -CH3, and R 3 is hydrogen.

[0057] In some embodiments, the compound of formula (I), or a pharma- ceutically acceptable salt thereof, has formula (Ib): [ka] It is a compound of the formula:

[0058] In some embodiments, in the compound of formula (Ib), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is hydrogen, and R 3 is hydrogen.

[0059] In some embodiments, in the compound of formula (Ib), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is -[CH(R 4a )] m NH2, m is 1, and R 4a is a C alkyl (e.g., isopropyl).

[0060] In some embodiments, in the compound of formula (Ib), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is -[CH(R 4a )] m NH2, m is 1, and R 4a is C alkyl (e.g., methyl).

[0061] In some embodiments, in the compound of formula (Ib), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4is -[CH(R 4a )] m NH2, m is 1, and R 4a is a C2 alkyl (e.g., ethyl).

[0062] In some embodiments, in the compound of formula (Ib), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is -[CH(R 4a )] m NH2, m is 1, and R 4a is a C4 alkyl (e.g., isobutyl or tert-butyl).

[0063] In some embodiments, in the compound of formula (Ib), R 1 is hydrogen and Y is -(CH2) n- where n is 1 and R 2 is -(C=X)R 4 and R 3 is hydrogen, X is O, and R 4 is -[CH(R 4a )] m NH2, m is 1, and R 4a is hydrogen.

[0064] In some embodiments, disclosed is a compound of formula (II): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, R 11 is hydrogen, -CH3, and [ka] wherein * indicates (S) stereochemistry; Y 1is -(CH2) p - or -(C=O)-; p is an integer selected from 1 and 2; R 11a is C1-C4 alkyl; R 12 is hydrogen, -CH3, and -(C=X 1 )R 14 and R 13 is hydrogen or -CH3; or R 12 and R 13 are linked together with the nitrogen to which they are attached to form a six-membered heterocycle; X 1 is NH or O; R 14 is -CH3 or [ka] where * indicates (S) stereochemistry; R 14a is C1-C4 alkyl; and q is an integer selected from 0 and 1; or a pharma- ceutically acceptable salt thereof.

[0065] In some embodiments, in the compound of Formula (II), R 11 is hydrogen, and Y 1 is -(CH2) p- where p is 1 and R 12 is hydrogen, and R 13 is hydrogen.

[0066] In some embodiments, in the compound of Formula (II), R 11 is hydrogen, and Y 1 is -(CH2) p- p is 1, and R 12 and R 13are linked together with the nitrogen to which they are attached to form a 6-membered nitrogen-containing heterocycle. In some embodiments, the nitrogen-containing 6-membered heterocycle is a morpholinyl ring. In some embodiments, the nitrogen-containing 6-membered heterocycle is a piperazinyl ring.

[0067] In some embodiments, in the compound of Formula (II), R 11 is hydrogen, and Y 1 is -(CH2) p- where p is 1 and R 12 is -CH3, and R 13 is hydrogen.

[0068] In some embodiments, in the compound of Formula (II), R 11 is hydrogen, and Y 1 is -(CH2) p- where p is 1 and R 12 is -CH3, and R 13 is -CH3.

[0069] In some embodiments, in the compound of Formula (II), R 11 is hydrogen, and Y 1 is -(CH2) p- where p is 1 and R 12 is -(C=X 1 )R 14 and R 13 is hydrogen, and X 1 is NH and R 14 teeth, [ka] and q is 0.

[0070] In some embodiments, in the compound of Formula (II), R 11 is hydrogen, and Y 1 is -(CH2) p- where p is 1 and R 12 is -(C=X 1 )R 14 and R 13is hydrogen, and X 1 is O and R 14 teeth, [ka] and q is 0.

[0071] In some embodiments, in the compound of Formula (II), R 11 is hydrogen, and Y 1 is -(CH2) p- where p is 1 and R 12 is -(C=X 1 )R 14 and R 13 is hydrogen, and X 1 is O and R 14 teeth, [ka] q is 1, and R 14a is a C alkyl (e.g., isopropyl).

[0072] In some embodiments, in the compound of Formula (II), R 11 is hydrogen, and Y 1 is -(CH2) p- where p is 1 and R 12 is -(C=X 1 )R 14 and R 13 is hydrogen, and X 1 is O and R 14 teeth, [ka] q is 1, and R 14a is a C2 alkyl (e.g., ethyl).

[0073] In some embodiments, in the compound of Formula (II), R 11 is hydrogen, and Y 1 is -(CH2) p- where p is 1 and R 12is -(C=X 1 )R 14 and R 13 is hydrogen, and X 1 is O and R 14 teeth, [ka] q is 1, and R 14a is C alkyl (e.g., methyl).

[0074] In some embodiments, in the compound of Formula (II), R 11 is hydrogen, and Y 1 is -(CH2) p- where p is 1 and R 12 is -(C=X 1 )R 14 and R 13 is hydrogen, and X 1 is O, and R 14 is -CH3.

[0075] In some embodiments, in the compound of Formula (II), R 11 is -CH3, and Y 1 is -(CH2) p- where p is 1 and R 12 is hydrogen, and R 13 is hydrogen.

[0076] In some embodiments, in the compound of Formula (II), R 11 teeth, [ka] and R 11a is C alkyl (e.g., isopropyl), and Y 1 is -(CH2) p- where p is 1 and R 12 is hydrogen, and R 13 is hydrogen.

[0077] In some embodiments, in the compound of Formula (II), R11 teeth, [ka] and R 11a is C alkyl (e.g., methyl), and Y 1 is -(CH2) p- where p is 1 and R 12 is hydrogen, and R 13 is hydrogen.

[0078] In some embodiments, in the compound of Formula (II), R 11 is hydrogen, and Y 1 is -(CH2) p- where p is 2 and R 12 is hydrogen, and R 13 is hydrogen.

[0079] In some embodiments, in the compound of Formula (II), R 11 is hydrogen, and Y 1 is -(C=O) and R 12 is hydrogen, and R 13 is hydrogen.

[0080] In some embodiments, in the compound of Formula (II), R 11 is hydrogen, and Y 1 is -(C=O) and R 12 is -CH3, and R 13 is hydrogen.

[0081] In some embodiments, disclosed is a compound of formula (III): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, R 22 is hydrogen or [ka] where * indicates (S) stereochemistry; and R 24a is C1-C4 alkyl; or a pharma- ceutically acceptable salt thereof.

[0082] In some embodiments, in the compound of Formula (III), R 22 is hydrogen.

[0083] In some embodiments, in the compound of Formula (III), R 22 teeth, [ka] and R 24a is a C alkyl (e.g., isopropyl).

[0084] In some embodiments, in the compound of Formula (III), R 22 teeth, [ka] and R 24a is C alkyl (e.g., methyl).

[0085] In some embodiments, in the compound of Formula (III), R 22 teeth, [ka] and R 24a is a C2 alkyl (e.g., ethyl).

[0086] In some embodiments, in the compound of Formula (III), R 22 teeth, [ka] and R 24a is a C4 alkyl (e.g., isobutyl or tert-butyl).

[0087] In some embodiments, disclosed is a compound of formula (IV): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, R 11 teeth, [ka] where * indicates (S) stereochemistry, and R 11a is C1-C4 alkyl; or a pharma- ceutically acceptable salt thereof.

[0088] In some embodiments, disclosed is a compound of Table 1, or a pharma- ceutically acceptable salt thereof.

[0089] [Table 1]

[0090] [Table 2]

[0091] [Table 3]

[0092] [Table 4]

[0093] The phrase "C1-C4 alkyl" includes acyclic saturated alkyl moieties having 1 to 4 carbon atoms. Examples of C1-C4 alkyl moieties include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl.

[0094] The phrase "nitrogen-containing six-membered heterocycle" includes saturated cycloalkyl moieties in which at least one carbon has been replaced by nitrogen. Examples of nitrogen-containing six-membered heterocycles include piperidine, piperazine, morpholine, thiomorpholine, and hexahydro-1,3,5-triazine.

[0095] The phrase "pharmaceutically acceptable salts" includes acid addition or base salts which typically retain the biological effectiveness and properties of the compounds of Formulas (I), (Ia), (Ib), (II), (III), (IV), and Table 1, which are not biologically or otherwise undesirable. In many cases, the compounds of Formulas (I), (Ia), (Ib), (II), (III), (IV), and Table 1 may form acid and / or base salts by virtue of the presence of basic and / or carboxyl groups or groups similar thereto.

[0096] Pharmaceutically acceptable acid addition salts may be formed with inorganic and organic acids, such as acetate, aspartate, benzoate, besylate, bromide / hydrobromide, bicarbonate / carbonate, hydrogensulfate / sulfate, camphorsulfonate, chloride / hydrochloride, chlortheophyllonate, citrate, ethanedisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide / iodide, isethionate, lact ... The salts may be tobionate, lauryl sulfate, malate, maleate, malonate, mandelate, mesylate, methylsulfate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, palmoate, phosphate / hydrogen phosphate / dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, subsalicylate, sulfate / hydrogen sulfate, tartrate, tosylate, and trifluoroacetate. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, trifluoroacetic acid, sulfosalicylic acid, and the like.

[0097] Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, ammonia and ammonium salts, and metals from columns I-XII of the periodic table. In certain embodiments, salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium, and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines, such as naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine, and tromethamine.

[0098] Pharmaceutically acceptable salts of the compounds of Formulas (I), (Ia), (Ib), (II), (III), (IV), and Table 1 may be synthesized from a basic or acidic moiety by conventional chemical methods. Generally, such salts are prepared by reacting the free acid form of these compounds with a stoichiometric amount of an appropriate base (e.g., Na + , Ca 2+ , Mg 2+ , or K +The salts may be prepared by reacting the free base forms of these compounds with a stoichiometric amount of an appropriate acid, such as hydroxide, carbonate, bicarbonate, or the like. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. In general, it is desirable to use non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, where practicable. Additional lists of suitable salts can be found, for example, in "Remington's Pharmaceutical Sciences," 20th ed., Mack Publishing Company, Easton, Pa., (1985); Berge et al., "J.Pharm.Sci., 1977, 66, 1-19, and "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).

[0099] Any formula provided herein is also intended to represent unlabeled and isotopically labeled forms of the compounds of formula (I), (Ia), (Ib), (II), (III), (IV), and Table 1, or pharma- ceutically acceptable salts thereof. Isotopically labeled compounds have a structure represented by the formula provided herein, except that one or more atoms are replaced by an atom of the same element but of a different mass number. Examples of isotopes that may be incorporated into the compounds of formula (I), (Ia), (Ib), (II), (III), (IV), and Table 1, and pharma- ceutically acceptable salts thereof, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, e.g., 2 H, 3 H, 11 C. 13 C. 14 C. 15 N, 35 S, 36 Cl, and 125Isotopically labeled compounds of formula (I), (Ia), (Ib), (II), (III), (IV), and Table 1 may generally be prepared by conventional techniques known to those skilled in the art, or may be prepared by processes similar to those illustrated in the accompanying Examples, substituting the appropriate isotopically labeled reagent for the non-labeled reagent previously used.

[0100] The compounds of formula (I), (Ia), (Ib), (II), (III), (IV), and Table 1, or pharma- ceutically acceptable salts thereof, may have different isomeric forms. The terms "optical isomer", "stereoisomer", or "diastereoisomer" refer to any of the various stereoisomeric configurations that may exist for a given compound of formula (I), (Ia), (Ib), (II), (III), (IV), and Table 1, or pharma- ceutically acceptable salts thereof. Because substituents may be attached to chiral centers of carbon atoms, it is understood that the compounds of the present disclosure include enantiomers, diastereomers, and racemates. The term "enantiomer" includes pairs of stereoisomers that are non-superimposable mirror images of one another. A 1:1 mixture of a pair of enantiomers is a racemic mixture. This term is used to denote a racemic mixture, where appropriate. The term "diastereomer" or "diastereoisomer" includes stereoisomers that have at least two asymmetric atoms but are not mirror images of one another. Absolute stereochemistry is specified according to the Cahn-Ingold-Prelog RS system. When compounds are pure enantiomers, the stereochemistry at each chiral center may be specified as either R or S. Resolved compounds whose absolute configuration is unknown may be designated as (+) or (-) depending on the way (dextrorotatory or levorotatory) they rotate plane polarized light at the wavelength of the sodium D line. Some of the compounds of formulae (I), (Ia), (Ib), (II), (III), (IV), and Table 1, or pharma- ceutically acceptable salts thereof, contain one or more asymmetric centers or axes, which may give rise to enantiomers, diastereomers, or other stereoisomers that may be defined in terms of absolute stereochemistry as (R)- or (S)-. The present disclosure is intended to include all such possible isomers, including racemic mixtures, optically pure forms, and intermediate mixtures. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques known in the art (e.g., chiral HPLC).

[0101] Also disclosed herein are Intermediates 1-56 and salts thereof in the Examples.

[0102] Pharmaceutical Compositions In some embodiments, disclosed is a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

[0103] The phrase "pharmaceutically acceptable carrier" includes compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, within the scope of sound medical judgment, as determined by one of ordinary skill in the art.

[0104] The compositions of the present disclosure may be in a form suitable for oral use (e.g., tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), or in a form suitable for topical use (e.g., creams, ointments, gels, or aqueous or oily solutions or suspensions), or in a form suitable for administration by inhalation (e.g., as a finely divided powder or liquid aerosol), or in a form suitable for administration by insufflation (e.g., as a finely divided powder), or in a form suitable for parenteral administration (e.g., as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, or intramuscular administration, or as a suppository for rectal administration).

[0105] The amount of active ingredient that is combined with one or more pharma-ceutically acceptable carriers to produce a single dosage form will necessarily vary depending on the host treated and the particular route of administration.For further information on routes of administration and dosage regimens, the reader is referred to Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990, Volume 5, Chapter 25.3.

[0106] Therapeutic utility The compounds are useful in therapy as arginase inhibitors.

[0107] In one aspect, disclosed is a method of treating cancer in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof.

[0108] In one aspect, disclosed is a method of treating a respiratory inflammatory disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof.

[0109] In one aspect, disclosed is a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, for use in treating cancer.

[0110] In one aspect, disclosed is a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, for use in treating a respiratory inflammatory disease.

[0111] In one aspect, disclosed is the use of a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer.

[0112] In one aspect, disclosed is the use of a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for treating a respiratory inflammatory disease.

[0113] In one aspect, disclosed is a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, for use in treating cancer.

[0114] In one aspect, disclosed is a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, for use in treating a respiratory inflammatory disease.

[0115] The term "cancer" includes, for example, renal cell carcinoma, squamous cell carcinoma of the head and neck, lung cancer (e.g., small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), mesothelioma), pancreatic cancer, colorectal cancer, breast cancer, acute myeloid leukemia (AML), prostate cancer, gastric cancer, bladder cancer, melanoma, renal cancer, and ovarian cancer. In some embodiments, the cancer has metastasized. In some embodiments, the cancer is associated with modulation of Arginase 1 and / or Arginase 2.

[0116] In some embodiments, the cancer is associated with elevated plasma arginase 1 levels. In some embodiments, the cancer is associated with decreased plasma arginine levels. In some embodiments, the cancer is associated with both elevated plasma arginase 1 levels and decreased plasma arginine levels. In some embodiments, the cancers associated with elevated plasma arginase 1 levels and / or decreased plasma arginine levels include renal cell carcinoma, head and neck squamous cell carcinoma, lung cancer (e.g., small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), mesothelioma), pancreatic cancer, colorectal cancer, and breast cancer.

[0117] In some embodiments, the cancer (e.g., acute myeloid leukemia and prostate cancer) secretes Arginase 2.

[0118] In some embodiments, the cancer (e.g., lung cancer (small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), gastric cancer, bladder cancer, colorectal cancer, melanoma, squamous cell carcinoma of the head and neck, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, and renal cancer) is associated with Arginase 1-positive tumor-infiltrating immune cells.

[0119] The term "respiratory inflammatory disease" refers to an inflammatory condition or disorder that affects air spaces, pulmonary vasculature, pulmonary interstitium, or a combination thereof. They may be isolated to the lungs or may involve multiple organs. In one embodiment, the respiratory inflammatory disease is an inflammatory lung disease. In another embodiment, the inflammatory lung disease is non-infectious. In some embodiments, the respiratory inflammatory disease is associated with the regulation of arginase 1 and / or arginase 2.

[0120] In some embodiments, the respiratory inflammatory disease is asthma, chronic obstructive pulmonary disease (COPD), chemically induced pulmonary fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, or a combination thereof. In some embodiments, the respiratory inflammatory disease is chronic obstructive pulmonary disease (COPD) or asthma.

[0121] In one aspect, disclosed is a method of inhibiting arginase in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof.

[0122] In one aspect, disclosed is a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), and Table 1, or a pharma- ceutically acceptable salt thereof, for use in inhibiting arginase.

[0123] In one aspect, disclosed is the use of a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting arginase.

[0124] In one aspect, disclosed is a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, for use in inhibiting arginase.

[0125] The term "arginase" includes manganese-containing enzymes belonging to the urea hydrolase family that catalyze the fifth and final step in the urea cycle, which converts L-arginine to L-ornithine and urea. The term "arginase" includes two isoenzymes of the enzyme, such as arginase 1, which functions in the urea cycle and is present primarily in the cytoplasm of the liver, and arginase 2, which is present in the mitochondria of several tissues in the body and is involved in regulating the arginine / ornithine concentration in cells. In some embodiments, the compounds of formulas (I), (Ia), (Ib), (II), (III), (IV), and Table 1, or pharma- ceutically acceptable salts thereof, are selective for arginase 1. In some embodiments, the compounds of formulas (I), (Ia), (Ib), (II), (III), (IV), and Table 1, or pharma-ceutically acceptable salts thereof, are selective for arginase 2. In some embodiments, the compounds of Formula (I), (Ia), (Ib), (II), (III), (IV), and Table 1, or pharma- ceutically acceptable salts thereof, inhibit both Arginase 1 and Arginase 2.

[0126] The phrase "effective amount" includes an amount of a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, that will elicit a biological or medical response in a subject (e.g., reducing or inhibiting arginase or cancer-related enzymatic or protein activity, ameliorating symptoms of cancer, or slowing or delaying the progression of cancer). In some embodiments, the phrase "effective amount" includes an amount of a compound of Formula (I), (Ia), (Ib), (II), (III), (IV), or Table 1, or a pharma- ceutically acceptable salt thereof, that, when administered to a subject, is effective to at least partially alleviate, inhibit, and / or ameliorate cancer, or inhibit arginase, and / or reduce or inhibit tumor growth or proliferation of cancer cells in the subject.

[0127] The term "subject" includes warm-blooded mammals, including, for example, primates, dogs, cats, rabbits, rats, and mice. In some embodiments, the subject is a primate, such as a human. In some embodiments, the subject is suffering from cancer. In some embodiments, the subject is in need of treatment (e.g., the subject would benefit biologically or medically from treatment). In some embodiments, the subject has elevated plasma arginase 1 levels. In some embodiments, the subject has reduced arginine levels. In some embodiments, the patient has elevated plasma arginase 1 levels and reduced arginine levels. In some embodiments, the subject has a cancer that secretes arginase 2 (e.g., acute myeloid leukemia or prostate cancer). In some embodiments, the subject has arginase 1-positive tumor-infiltrating immune cells.

[0128] The terms "inhibit," "inhibit," or "inhibiting" include a decrease in the baseline activity of a biological activity or biological process. In some embodiments, the compounds of Formula (I), (Ia), (Ib), (II), (III), (IV), and Table 1, or pharma- ceutically acceptable salts thereof, inhibit arginase.

[0129] The terms "treat", "treating", and "treatment" include reducing or inhibiting enzyme or protein activity associated with arginase, or ameliorating one or more symptoms of cancer in a subject, or slowing or delaying the progression of cancer in a subject. The terms "treat", "treating", and "treatment" also include reducing or inhibiting the growth of a tumor or the proliferation of cancer cells in a subject. The present invention includes the following aspects. [1] Formula (I): [ka] or a pharma- ceutically acceptable salt thereof, During the ceremony, R 1 is hydrogen, -CH 3 , and -(C=O)CH(R 1a )NH 2 Selected from; R 1a is C 1 ~C 4 is alkyl; Y is -(CH 2 ) n - or -(C=O)-; n is an integer selected from 1 and 2; R 2 is hydrogen, -CH 3 , and -(C=X)R 4 and R 3 is hydrogen or -CH 3 Is it; or R 2 and R 3 are linked together with the nitrogen to which they are attached to form a six-membered heterocycle; X is NH or O; R 4 is -CH 3 or -[CH(R 4a )] m NH 2 and; m is an integer selected from 0 or 1; and R 4a is hydrogen or C 1 ~C 6 is alkyl, A compound, or a pharma- ceutically acceptable salt thereof. [2] The compound of formula (I) or a pharma- ceutically acceptable salt thereof has the formula (Ia):

change

change

change

change

change

change

change

change

change

[10] The compound according to any one of items 1 to 7, or a pharma- ceutically acceptable salt thereof, for use in treating cancer.

[11] The pharmaceutical composition according to item 8, for treating cancer.

[12] Use of the compound according to any one of items 1 to 7, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer.

[13] A method for treating a respiratory inflammatory disease, comprising administering to a subject a therapeutically effective amount of the compound according to any one of items 1 to 7 or a pharma- ceutical acceptable salt thereof.

[14] The compound according to any one of items 1 to 7, or a pharma- ceutically acceptable salt thereof, for use in treating a respiratory inflammatory disease.

[15] The pharmaceutical composition according to item 8, for treating a respiratory inflammatory disease.

[16] Use of the compound according to any one of items 1 to 7, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for treating a respiratory inflammatory disease. EXAMPLES

[0130] Aspects of the present disclosure can be further defined by reference to the following non-limiting examples, which detail the preparation of certain compounds and intermediates of the present disclosure, and methods of using the compounds of the present disclosure. It will be apparent to those skilled in the art that numerous modifications, both to materials and methods, can be made without departing from the scope of the present disclosure.

[0131] Unless otherwise stated, (i) all syntheses are carried out at ambient temperature (i.e., in the range of 17-25° C.) and under an atmosphere of an inert gas, such as nitrogen, unless otherwise specified; (ii) evaporation is carried out by rotary evaporation or by using a Genevac apparatus or a Biotage v10 evaporator under vacuum, followed by removal of residual solids by filtration, followed by a work-up procedure; (iii) Flash chromatography purification was carried out on an automated Teledyne Isco CombiFlash® Rf or Teledyne Isco CombiFlash® Companion® using prepacked RediSep Rf Gold™ silica columns (20-40 μm, spherical particles), GraceResolv™ cartridges (Davisil® silica), or Silicycle cartridges (40-63 μm). (iv) Preparative chromatography was performed on a Gilson preparative HPLC instrument equipped with UV collection; alternatively, preparative chromatography was performed on a Waters AutoPurification HPLC-MS instrument equipped with MS and UV trigger collection; (v) Chiral preparative chromatography was performed on a Gilson instrument (233 injector / fraction collector, 333 & 334 pumps, 155 UV detector) with UV collection, or a Varian Prep Star instrument (2×SD1 pumps, 325 UV detector, 701 fraction collector) pump (running with a Gilson 305 injection); alternatively, chiral preparative chromatography was performed on a Waters Prep 100 SFC-MS instrument with MS and UV trigger collection, or a Thar MultiGram III SFC instrument with UV collection. (vi) yields, if any, are not necessarily the maximum achievable; (vii) In general, the structures of the end-products of formula I are confirmed by nuclear magnetic resonance (NMR) spectroscopy; NMR chemical shift values ​​are measured on the delta scale [proton magnetic resonance spectra were determined using a Bruker Avance 500 (500 MHz), Bruker Avance 400 (400 MHz), Bruker Avance 300 (300 MHz), or Bruker DRX (300 MHz) instrument]; measurements were taken at ambient temperature unless otherwise specified; and the following abbreviations are used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of doublet; ddd, doublet of doublet of doublet; dt, doublet of triplet; bs, broad signal. (viii) In general, the final products of formula I were also characterized by liquid chromatography (LCMS or UPLC) followed by mass spectrometry; UPLC was run using a Waters UPLC equipped with a Waters SQ mass spectrometer (column temperature 40° C., UV=220-300 nm or 190-400 nm, mass spectrometry=ESI with positive / negative switching) at a flow rate of 1 mL / min over 1.50 min (total runtime to return equilibrium to starting conditions etc. was 1.70 min) using a solvent system of 97% A+3% B to 3% A+97% B, where A=0.1% formic acid or 0.05% trifluoroacetic acid in water (for acidic workup), or 0.1% ammonium hydroxide in water (for basic workup), and B=acetonitrile. The column used for acidic analysis was a Waters Acquity HSS T3 (1.8 μm, 2.1×50 mm) and the column used for basic analysis was a Waters Acquity BEH C18 (1.7 μm, 2.1×50 mm). Alternatively, UPLC was performed using a Waters UPLC equipped with a Waters SQ mass spectrometer (column temperature 30° C., UV=210-400 nm, mass analysis=ESI with positive / negative switching) with a flow rate of 1 mL / min using a solvent gradient of 2-98% B over 1.5 min (total run time to return equilibrium to starting conditions was 2 min) where A=0.1% formic acid in water and B=0.1% formic acid in acetonitrile (for acidic treatment) or A=0.1% ammonium hydroxide in water and B=acetonitrile (for basic treatment).The column used for acidic analysis was a Waters Acquity HSS T3 (1.8 μm, 2.1×30 mm) and the column used for basic analysis was a Waters Acquity BEH C18 (1.7 μm, 2.1×30 mm); LCMS was performed using a Waters Alliance HT (2795) and Phenomenex Gemini-NX C18 (5 μm, 110A, 2.1×50 mm column with a Waters ZQ ESCi mass spectrometer, with a flow rate of 1.1 mL / min, with a 0.5 min hold from 95% A to 95% B over 4 min, where A=0.1% formic acid in acetonitrile and B=0.1% formic acid (for acidic workup), or A=0.1% ammonium hydroxide in water and B=acetonitrile (for basic workup). In addition, a Shimadzu UFLC with a Shimadzu LCMS-2020 mass spectrometer, and a Waters HSS C18 (1.8 μm, 2.1 × 50 mm), or Shim-pack XR-ODS (2.2 μm, 3.0 × 50 mm), or Phenomenex Gemini-NX C18 (3 μm, 3.0 × 50 mm) columns were used, with a flow rate of 0.7 mL / min (for Waters HSS C18 columns), 1.0 mL / min (for Shim-pack XR-ODS columns), or 1.2 mL / min (for Phenomenex Gemini-NX LCMS was run over 2.2 min with a 0.6 min hold at 95% A to 95% B at a flow rate of 1000 s for C18, where A = 0.1% formic acid or 0.05% trifluoroacetic acid in water (for acidic workup), or 0.1% ammonium hydroxide or 6.5 mM ammonium carbonate in water (for basic workup), and B = acetonitrile. Molecular ions reported correspond to [M+H]+ unless otherwise stated; for molecules with multiple isotopic patterns (Br, Cl, etc.), the value reported is that obtained at the lowest isotopic mass unless otherwise stated. (ix) ion exchange purification was generally carried out using SCX-2 (Biotage) cartridges. (x) assessing the purity of intermediates by thin layer chromatography, mass spectroscopy, LCMS, UPLC / MS, HPLC (high performance liquid chromatography), and / or NMR analysis; (xi) The following abbreviations are used: EtOAc: ethyl acetate Et2O: Diethyl ether DMSO: Dimethyl sulfoxide LAH: Lithium aluminum hydride LiHMDS: Lithium hexamethyldisilazane MeOH: Methanol TFA: Trifluoroacetic acid MeCN: Acetonitrile LCMS: Liquid Chromatography Mass Spectrometry rt or RT: room temperature aq: water-based THF: tetrahydrofuran DCM: dichloromethane DMF: Dimethylformamide HATU: (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate) TBAF: Tetrabutylammonium fluoride AcOH: acetic acid DIAD: Diisopropyl azodicarboxylate Boc-Ala-OH: N-(tert-butoxycarbonyl)-L-alanine Boc-Val-OH: N-(tert-butoxycarbonyl)-L-valine HEPES: (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid).

[0132] Example 1: (2S,3R)-2-Amino-3-(aminomethyl)-6-boronohexanoic acid dihydrochloride [ka]

[0133] Intermediate 1: (S)-4-(allyloxy)-2-amino-4-oxobutanoic acid hydrochloride L-Aspartic acid (10.66 g, 80.09 mmol) was suspended in allyl alcohol (60.0 mL, 880 mmol) under an atmosphere of N2. To this suspension, chlorotrimethylsilane (31.0 mL, 240 mmol) was added dropwise via syringe pump at a rate of 1 mL / min. The reaction mixture was stirred at room temperature for 16 h. The reaction was diluted with ice-cold Et2O (100 mL) and the suspension was filtered off. The solid was washed with ice-cold Et2O (3 x 15 mL) and dried to give (S)-4-(allyloxy)-2-amino-4-oxobutanoic acid hydrochloride (Intermediate 1, 12.7 g, 76% yield) as an amorphous white solid, which was used in the next step without further purification. 1 H NMR(300MHz,D2O)δ 3.14(2H,d),4.25(1H,t),4.70(2H,d),5.26-5.48(2H,m),5.89-6.08(1H,m);m / z:(ES + ) [M+H] + =174.

[0134] Intermediate 2: (S)-4-Allyl 1-tert-butyl 2-(benzyloxycarbonylamino)succinate (S)-4-(allyloxy)-2-amino-4-oxobutanoic acid hydrochloride (Intermediate 1, 11.58 g, 55.24 mmol) was dissolved in water (100 mL) and 1,4-dioxane (100 mL). Sodium carbonate (23.0 g, 220 mmol) was added portionwise at room temperature and the reaction was stirred for 5 min. Benzyl chloroformate (8.3 mL, 58 mmol) was added dropwise to the reaction via syringe pump at a rate of 1 mL / min. The biphasic reaction mixture was stirred for 4 h at room temperature. The crude reaction was quenched with concentrated aqueous HCl until the pH was <1. The layers were separated and the aqueous layer was extracted with EtOAc (2 x 25 mL). The combined organics were dried over MgSO4, filtered, and concentrated to give a colorless oil. The crude carboxylic acid was dissolved in DCM (100 mL) in a pressure flask and cooled to -78 °C. Sulfuric acid (3.0 mL, 56 mmol) was added immediately followed by pre-condensed isobutylene (66.0 mL, 710 mmol). The flask was sealed and stirred for 3 days to allow the ice bath to expire. The reaction was poured into saturated aqueous sodium bicarbonate (200 mL) and stirred for 30 min. The layers were separated and the aqueous layer was extracted with DCM (2 x 20 mL). The combined organics were dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (S)-4-allyl 1-tert-butyl 2-(benzyloxycarbonylamino)succinate (Intermediate 2, 12.2 g, 61% yield) as a colorless oil. 1 H NMR(300MHz,CDCl3)δ 1.47(9H,s),2.76-2.93(1H,dd),2.94-3.12(1H,dd),4.48-4.57(1H,m),4.60(2H,dq),5.14(2H,s),5.26(1H,dq),5.33(1H,dq),5.71(1H,br d),5.91(1H,ddt),7.31-7.48(5H,m);m / z:(ES + ) [M+H] + =381.

[0135] Intermediate 3: 2-((S)-1-(benzyloxycarbonylamino)-2-tert-butoxy-2-oxoethyl)pent-4-enoic acid A solution of LiHMDS (1M in toluene, 100 mL, 100 mmol) was placed in an oven-dried multineck flask and diluted with THF (50 mL) under an atmosphere of N2. The solution was cooled to -78°C and (S)-4-allyl 1-tert-butyl 2-(benzyloxycarbonylamino)succinate (Intermediate 2, 12.2 g, 33.5 mmol) was added dropwise to the reaction flask as a solution in THF (50 mL). The reaction was stirred at -78°C for 80 min. Chlorotrimethylsilane (17.0 mL, 133 mmol) was added and the reaction was stirred at -78°C for an additional 1 h. The reaction was then heated to 60°C for 160 min. The reaction mixture was cooled to room temperature and quenched with 2M aq. HCl (67 mL). After stirring vigorously for 30 min, the layers were separated and the aqueous layer was extracted with EtOAc (2×30 mL). The combined organics were dried over MgSO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (DCM / MeOH) to afford 2-((S)-1-(benzyloxycarbonylamino)-2-tert-butoxy-2-oxoethyl)pent-4-enoic acid (Intermediate 3, 12.0 g, 99%) as an inseparable mixture of diastereomers in approximately 1.7:1 ratio. 1 H NMR(300MHz,CDCl3)δ 1.41(3.4H,s)1.43(5.6H,s),2.19-2.43(1H,m),2.44-2.66(1H,m),2.81-2.99(0.65H,m),3.08-3.25(0.35H ,m),4.48-4.63(1H,m),4.97-5.20(4H,m),5.52-5.71(1H,m),5.71-5.94(1H,m),7.25-7.39(5H,m);m / z:(ES + ) [M+H] + =364.

[0136] Intermediate 4: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(hydroxymethyl)hex-5-enoate, and Intermediate 5: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(hydroxymethyl)hex-5-enoate 2-((S)-1-(benzyloxycarbonylamino)-2-tert-butoxy-2-oxoethyl)pent-4-enoic acid (Intermediate 3, 12.0 g, 33.0 mmol) was dissolved in THF (60 mL) and cooled to −10° C. under an atmosphere of N2. N-Methylmorpholine (3.7 mL, 34 mmol) was added and the reaction was stirred for 5 min at −10° C. followed by the addition of ethyl chloroformate (3.2 mL, 33 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 40 min. The resulting suspension was filtered at 0° C. directly into a solution of sodium borohydride (3.0 g, 79 mmol) in water (60 mL). After the addition, the reaction was allowed to warm to room temperature and stirred for 3 h. The reaction mixture was cooled to 0° C. and carefully quenched with 2 M aq. HCl (20 mL). The layers were separated and the aqueous layer was extracted with EtOAc (2×25 mL). The combined organics were dried over MgSO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(hydroxymethyl)hex-5-enoate (Intermediate 4, 5.77 g, 50% yield) and (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(hydroxymethyl)hex-5-enoate (Intermediate 5, 3.96 g, 34% yield) as colorless oils.

[0137] Intermediate 4: 1H NMR(300MHz,CDCl3)δ 1.46(9H,s),1.70-1.85(1H,m),1.85-1.99(1H,m),2.18-2.37(1H,m),3.26(1 H,t),3.63(1H,dd),4.58(1H,dd),4.92-5.06(2H,m),5.10(2H,s),5.55(1H,br d),5.60-5.78(1H,m),7.26-7.39(5H,m);m / z:(ES + ) [M+H] + =350.

[0138] Intermediate 5: 1 H NMR(300MHz,CDCl3)δ 1.45(9H,s),2.03-2.12(1H,m),2.13-2.23(2H,m),3.65(2H,qd),4.34(1H,br dd),5.00-5.15(4H,m),5.62-5.90(2H,m),7.25-7.41(5H,m);m / z:(ES + ) [M+H] + =350.

[0139] Intermediate 6: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((methylsulfonyloxy)methyl)hex-5-enoate To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(hydroxymethyl)hex-5-enoate (Intermediate 4, 4.61 g, 13.2 mmol) in DCM (100 mL) at 0° C., triethylamine (7.4 mL, 53 mmol) and methanesulfonyl chloride (2.6 mL, 33 mmol) were added successively. The reaction was allowed to warm to room temperature and stirred for 90 min. The crude mixture was diluted with DCM (25 mL) and washed successively with saturated aqueous sodium bicarbonate, water, and brine (25 mL each). The organic layer was dried over MgSO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((methylsulfonyloxy)methyl)hex-5-enoate (Intermediate 6, 5.3 g, 93% yield) as a pale yellow oil. 1 H NMR(300MHz,CDCl3)δ 1.46(9H,s),1.96-2.19(2H,m),2.36-2.58(1H,m),2.97(3H,s),4.00-4.23(2H,m),4.52(1H,br d),5.00-5.17(4H,m),5.34(1H,br d),5.60-5.83(1H,m),7.27-7.37(5H,m);m / z:(ES + ) [M+H] + =445.

[0140] Intermediate 7: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((methylsulfonyloxy)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate Bis(1,5-cyclooctadiene)diiridium(I) dichloride (0.25 g, 0.37 mmol) and bis(diphenylphosphino)methane (0.28 g, 0.74 mmol) were placed in an oven-dried round-bottom flask. The flask was sealed and purged with N2. The solid was dissolved in DCM (35 mL) and to this solution was slowly added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4.00 mL, 28.0 mmol). The reaction was stirred at room temperature for 10 min. To the reaction was added (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((methylsulfonyloxy)methyl)hex-5-enoate (Intermediate 6, 5.27 g, 12.3 mmol) as a solution in DCM (30 mL) and the reaction mixture was stirred overnight. The reaction mixture was cooled to 0° C. and quenched with MeOH (6 mL) and water (50 mL). The layers were separated and the aqueous layer was extracted with DCM (2×15 mL). The combined organics were dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to afford (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((methylsulfonyloxy)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 7, 5.84 g, 85% yield) as a yellow gum. 1 H NMR(300MHz,CDCl3)δ 0.73(2H,t),1.20(12H,s),1.24-1.42(4H,m),1.45(9H,s),2.30-2.50(1H,m),2.97(3H,s),3.98(1H,t),4.18(1H,dd),4.50(1H,br d),5.02-5.15(2H,m),5.35(1H,br d),7.27-7.42(5H,m);m / z:(ES + )[M+NH4] + =573.

[0141] Intermediate 8: (2S,3R)-tert-butyl 3-(azidomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((methylsulfonyloxy)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 7, 5.84 g, 10.5 mmol) in DMF (30 mL) was added sodium azide (3.3 g, 51 mmol). The reaction was heated to 55° C. and stirred under an atmosphere of N2 for 16 h. An additional portion of sodium azide (200 mg, 3 mmol) was added and the reaction was stirred at 55° C. for an additional 4 h. The reaction mixture was cooled to room temperature and diluted with water (100 mL). The layers were separated and the aqueous layer was extracted with ether (3×35 mL). The combined organics were washed with brine (50 mL), then dried over MgSO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3R)-tert-butyl 3-(azidomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 8, 3.52 g, 67% yield) as a colorless oil. 1 H NMR(300MHz,CDCl3)δ 0.73(2H,t),1.20(12H,s),1.22-1.40(4H,m),1.45(9H,s),2.04-2.20(1H,m),3.15-3.30(1H,m),3.31-3.43(1H,m),4.46(1H,br d),5.10(2H,s),5.37(1H,br d),7.26-7.40(5H,m);m / z:(ES + )[M+NH4] + =520.

[0142] Intermediate 9: (2S,3R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of (2S,3R)-tert-butyl 3-(azidomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 8, 2.16 g, 4.29 mmol) in EtOAc (15 mL) was added Pd / C (10 wt%, 0.46 g, 0.43 mmol) and di-tert-butyl-dicarbonate (2.50 mL, 10.8 mmol). The flask was equipped with a balloon of H2 and the suspension was stirred at room temperature for 2 h. The reaction mixture was filtered through diatomaceous earth and rinsed with EtOAc. The filtrate was concentrated to give a cloudy colorless oil, which was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 9, 1.65 g, 71% yield) as a white foam. 1 H NMR(300MHz,CDCl3)δ 0.67-0.73(2H,m),0.95-1.16(2H,m),1.20(12H,s),1.37-1.47(29H,m ),2.00-2.20(1H,m),2.36-2.56(1H,m),3.31-3.57(1H,m),4.34(1H,br d),5.14(1H,br d),5.68(1H,br s);m / z:(ES - )[M+HCOO - ] - =587.

[0143] Example 1: (2S,3R)-2-Amino-3-(aminomethyl)-6-boronohexanoic acid dihydrochloride To a solution of (2S,3R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 9, 2.2 g, 4.1 mmol) in DCM (32 mL) was added a solution of HBr (33 wt% in AcOH, 6.0 mL, 36 mmol) and the reaction was stirred for 1 h at room temperature. The reaction was diluted with Et2O (10 mL) and concentrated. This process was repeated two more times. The residue was dissolved in Et2O (40 mL) and 2M aq. HCl (40 mL). Phenylboronic acid (0.989 g, 8.11 mmol) was added and the reaction was stirred for 2 h at room temperature. The layers were separated and the aqueous layer was washed with EtO (3x15 mL). The aqueous layer was lyophilized and purified by reverse phase chromatography (RediSep Rf Gold® C18Aq, 0-100% MeCN in water) to give (2S,3R)-2-amino-3-(aminomethyl)-6-boronohexanoic acid dihydrochloride (Example 1, 0.713 g, 64% yield) as a yellow solid. 1 H NMR(300MHz,D2O)δ 0.65-0.87(2H,m),1.32-1.56(4H,m),2.35-2.48(1H,m),3.12(2H,qd),4.09(1H,d);m / z:(ES + ) [M-H2O+H] + =187.

[0144] (2S,3R)-2-amino-3-(aminomethyl)-6-boronohexanoic acid dihydrochloride (Example 1, 713 mg, 2.57 mmol) was dissolved in MeOH (5 mL) and loaded onto a pre-equilibrated Porapak Rxn Cx (60 cc) ion exchange column. The resin was washed with MeOH (45 mL) followed by a 5% solution of NH3 in MeOH (45 mL) to elute the product. The product-containing fractions were collected and concentrated to give (2S,3R)-2-amino-3-(aminomethyl)-6-boronohexanoic acid (300 mg, 57% yield) as a white powdery residue, which exists as a 4:1 mixture of acyclic and cyclic coordination complexes. 1H NMR(300MHz,D2O)δ 0.49-0.92(2H,m),1.17-1.76(4H,m),2.03-2.18(0.8H,m),2.48-2.58(0.2H,m ),3.01(1.6H,d),3.16-3.26(0.4H,m),3.49(0.8H,d),3.71(0.2H,d);m / z:(ES + ) [M-H2O+H] + =187.

[0145] (2S,3R)-2-amino-3-(aminomethyl)-6-boronohexanoic acid (95 mg, 0.47 mmol) was dissolved in MeOH (3 mL) and para-toluenesulfonic acid monohydrate (266 mg, 1.40 mmol) was added. The reaction was stirred at room temperature for 20 h. The reaction mixture was concentrated and purified directly by reverse phase chromatography (RediSep Rf Gold® C18Aq, 0-100% MeCN in water) to give (2S,3R)-2-amino-3-(aminomethyl)-6-boronohexanoic acid ditosylate (180 mg, 71% yield) as a white solid. 1 H NMR(300MHz,D2O)δ 0.74-0.87(2H,m),1.38-1.61(4H,m),2.40(6H,s),2.45-2.48(1H,m),3 .15(2H,qd),4.01(1H,d),7.27-7.50(4H,m),7.63-7.79(4H,m);m / z:(ES + )[M-H2O-2TsOH+H] + =187.

[0146] Example 2: (2S,3R)-2-Amino-6-borono-3-(morpholinomethyl)hexanoic acid [ka]

[0147] Intermediate 10: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(morpholinomethyl)hex-5-enoate To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((methylsulfonyloxy)methyl)hex-5-enoate (Intermediate 6, 513 mg, 1.20 mmol) in DMF (5 mL) at room temperature was added morpholine (1.00 mL, 11.5 mmol) and potassium carbonate (829 mg, 6.00 mmol). The reaction mixture was heated to 80° C. and stirred for 16 h under an atmosphere of N2. The reaction was cooled to room temperature and diluted with water (50 mL). The layers were separated and the aqueous layer was extracted with Et2O (3×25 mL). The combined organics were dried over MgSO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to afford (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(morpholinomethyl)hex-5-enoate (Intermediate 10, 285 mg, 57% yield) as a colorless oil. 1 H NMR(300MHz,CDCl3)δ 1.45(9H,s),1.63-2.61(9H,m),3.54-3.79(4H,m),4.44(1H,br d),4.95-5.16(4H,m),5.63-5.87(1H,m),7.05(1H,br d),7.25-7.39(5H,m);m / z:(ES + ) [M+H] + =419.

[0148] Intermediate 11: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(morpholinomethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate Bis(1,5-cyclooctadiene)diiridium(I) dichloride (14 mg, 0.020 mmol) and bis(diphenylphosphino)methane (16 mg, 0.040 mmol) were placed in an oven-dried round-bottom flask. The flask was sealed and purged with N2. The solid was dissolved in DCM (3 mL) and to this solution was slowly added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.22 mL, 1.5 mmol). The reaction was stirred at room temperature for 10 min. To this reaction was added (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(morpholinomethyl)hex-5-enoate (Intermediate 10, 285 mg, 0.680 mmol) as a solution in DCM (2 mL) and the reaction mixture was stirred overnight. The reaction mixture was cooled to 0° C. and quenched with MeOH (2 mL) and water (10 mL). The layers were separated and the aqueous layer was extracted with DCM (2×10 mL). The combined organics were dried over MgSO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(morpholinomethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 11, 228 mg, 61% yield). 1 H NMR(300MHz,CDCl3)δ 0.64-0.83(2H,br t),1.20(12H,s),1.28-1.53(13H,m),1.93-2.63(4H,m),3.06-4.00(4 H,m),4.26-4.61 (1H,m),4.99-5.18(2H,m),7.26-7.39(5H,m) + ) [M+H] + =547.

[0149] Example 2: (2S,3R)-2-Amino-6-borono-3-(morpholinomethyl)hexanoic acid (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(morpholinomethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 11, 228 mg, 0.420 mmol) was dissolved in 6M aq. HCl (4.0 mL) and the solution was heated to 100° C. for 16 h. The reaction was cooled to room temperature, diluted with water (5 mL) and washed with Et2O (3×10 mL). The aqueous layer was lyophilized and purified by ion exchange chromatography (PoraPak Rxn CX 20 cc column). The resin was washed with MeOH (15 mL) followed by a 5% solution of NH3 in MeOH (15 mL) to elute the product. The product-containing fractions were collected and concentrated to give (2S,3R)-2-amino-6-borono-3-(morpholinomethyl)hexanoic acid (Example 2, 69 mg, 60% yield) as a white solid. 1 H NMR(300MHz,D2O)δ 0.72-0.88(2H,m),1.24-1.38(1H,m),1.40-1.58(3H,m),2.19-2.34(1H,m),2 .43-2.58(4H,m),2.62-2.77(2H,m),3.71-3.85(4H,m),3.88(1H,d);m / z:(ES + ) [M+H] + =275.

[0150] Example 3: (2S,3R)-2-Amino-6-borono-3-(piperidin-1-ylmethyl)hexanoic acid [ka]

[0151] Intermediate 12: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(piperidin-1-ylmethyl)hex-5-enoate A solution of oxalyl chloride (2M in DCM, 0.72 mL, 1.4 mmol) was placed in an oven-dried flask, diluted with DCM (3 mL) and cooled to -78 °C under an atmosphere of N2. DMSO (0.15 mL, 2.2 mmol) was added dropwise and the reaction was stirred at -78 °C for 10 min. (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(hydroxymethyl)hex-5-enoate (Intermediate 4, 250 mg, 0.72 mmol) was added slowly as a solution in DCM (3 mL) and the reaction was stirred at -78 °C for 30 min. N,N-Diisopropylethylamine (0.50 mL, 2.9 mmol) was added and the reaction was stirred at -78 °C for 1 h and then warmed to 0 °C with stirring for an additional 15 min. The reaction mixture was quenched with saturated aqueous NaHCO3 (10 mL) and diluted with DCM (50 mL). The layers were separated and the aq. layer was extracted with DCM (2x20 mL). The combined organics were dried over anhydrous Na2SO4, filtered, dried, filtered and concentrated until approximately 8 mL of solvent remained. The crude aldehyde was treated with piperidine (0.14 mL, 1.4 mmol), sodium triacetoxyborohydride (379 mg, 1.79 mmol) and acetic acid (0.041 mL, 0.72 mmol) and the resulting suspension was stirred at room temperature for 16 h. The reaction mixture was diluted with DCM (50 mL) and saturated aqueous NaHCO3 (10 mL) and the layers were separated. The aq. layer was extracted with DCM (2x10 mL). The combined organics were dried over Na2SO4, filtered and evaporated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to afford (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(piperidin-1-ylmethyl)hex-5-enoate (Intermediate 12, 269 mg, 90%) as a colorless oil. 1 H NMR(300MHz,CDCl3)δ ppm 1.39-1.53(15H,m),1.86-1.94(1H,m),2.07-2.46(8H,m),4.32(1H,d),5.0 3-5.15(4H,m),5.73-5.85(1H,m),7.26-7.35(5H,m),7.90(1H,d);m / z:(ES+ ) [M+H] + =417.

[0152] Intermediate 13: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(piperidin-1-ylmethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate Bis(1,5-cyclooctadiene)diiridium(I) dichloride (16 mg, 0.022 mmol) and bis(diphenylphosphino)methane (24 mg, 0.062 mmol) were placed in an oven-dried round-bottom flask. The flask was sealed and purged with N2. The solid was dissolved in DCM (3 mL) and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.20 mL, 1.4 mmol) was slowly added to the solution. The reaction was stirred at room temperature for 10 minutes. To the reaction was added (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(piperidin-1-ylmethyl)hex-5-enoate (Intermediate 12, 265 mg, 0.636 mmol) as a solution in DCM (3 mL) and the reaction mixture was stirred overnight. The reaction mixture was cooled to 0° C. and quenched with MeOH (2 mL) and water (10 mL). The layers were separated and the aqueous layer was extracted with DCM (2×10 mL). The combined organics were dried over MgSO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to afford (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(piperidin-1-ylmethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 13, 240 mg, 69% yield) as a colorless oil. m / z: (ES + ) [M+H] + =545.

[0153] Example 3: (2S,3R)-2-Amino-6-borono-3-(piperidin-1-ylmethyl)hexanoic acid (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(piperidin-1-ylmethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 13, 240 mg, 0.44 mmol) was dissolved in 6M aq. HCl (12 mL) and the solution was heated to 100° C. for 16 h. The reaction mixture was cooled to room temperature, diluted with HO (25 mL) and washed with EtOAc (2×15 mL). The aqueous layer was concentrated under reduced pressure and the resulting residue was purified by reverse phase chromatography (RediSep Rf Gold® C18, 0-50% acetonitrile in water) to give (2S,3R)-2-amino-6-borono-3-(piperidin-1-ylmethyl)hexanoic acid (Example 3, 79 mg, 36% yield) as a white solid. The resulting material was a 5.7:1 mixture of the title product and the C3 diastereomer. 1 H NMR(300MHz,D2O)δ 0.81-0.84(2H,m),1.42-1.58(5H,m),1.75-1.86(3H,m),1.93-1.99(2H,m),2.49(0.2H,s,br),2.62-2.64( m / z:(ES + ) [M+H] + =273.

[0154] Example 4: (2S,3R)-2-Amino-6-borono-3-((methylamino)methyl)hexanoic acid [ka]

[0155] Intermediate 14: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((4-methoxybenzyl)(methyl)amino)methyl)hex-5-enoate A solution of oxalyl chloride (2M in DCM, 0.57 mL, 1.1 mmol) was placed in an oven-dried flask, diluted with DCM (2 mL) and cooled to -78 °C under an atmosphere of N2. DMSO (0.12 mL, 1.7 mmol) was added dropwise and the reaction was stirred at -78 °C for 10 min. (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(hydroxymethyl)hex-5-enoate (Intermediate 4, 200 mg, 0.57 mmol) was added slowly as a solution in DCM (3 mL) and the reaction was stirred at -78 °C for 30 min. N,N-Diisopropylethylamine (0.40 mL, 2.3 mmol) was added and the reaction was stirred at -78 °C for 1 h and then warmed to 0 °C with stirring for an additional 15 min. The reaction mixture was quenched with saturated aqueous NaHCO3 (10 mL) and diluted with DCM (20 mL). The layers were separated and the aqueous layer was extracted with DCM (2 x 10 mL). The combined organics were dried over anhydrous Na2SO4, filtered and concentrated until approximately 8 mL of solvent remained. The crude aldehyde was treated with 1-(4-methoxyphenyl)-N-methylmethanamine (173 mg, 1.14 mmol), sodium triacetoxyborohydride (415 mg, 1.96 mmol) and acetic acid (0.033 mL, 0.57 mmol) and the resulting suspension was stirred at room temperature for 4 h. The reaction mixture was diluted with DCM (30 mL) and saturated aqueous NaHCO3 (20 mL) and the layers were separated. The aq. phase was extracted with DCM (3 x 30 mL). The combined organics were dried over anhydrous Na2SO4, filtered and evaporated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((4-methoxybenzyl)(methyl)amino)methyl)hex-5-enoate (Intermediate 14, 221 mg, 80% yield) as a colorless oil. m / z: (ES + ) [M+H] + =483.

[0156] Intermediate 15: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((4-methoxybenzyl)(methyl)amino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate Bis(1,5-cyclooctadiene)diiridium(I) dichloride (11 mg, 0.017 mmol) and bis(diphenylphosphino)methane (17 mg, 0.046 mmol) were placed in an oven-dried round-bottom flask. The flask was sealed and purged with N2. The solid was dissolved in DCM (3 mL) and to the solution was slowly added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.15 mL, 1.0 mmol). The reaction was stirred at room temperature for 10 min. To the reaction was added (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((4-methoxybenzyl)(methyl)amino)methyl)hex-5-enoate (Intermediate 14, 220 mg, 0.46 mmol) as a solution in DCM (3 mL) and the reaction mixture was stirred overnight. The reaction mixture was cooled to 0° C. and quenched with MeOH (2 mL) and water (10 mL). The layers were separated and the aqueous layer was extracted with DCM (2×10 mL). The combined organics were dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((4-methoxybenzyl)(methyl)amino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 15, 182 mg, 65% yield) as a colorless oil. m / z: (ES + ) [M+H] + =610.

[0157] Example 4: (2S,3R)-2-Amino-6-borono-3-((methylamino)methyl)hexanoic acid To a solution of (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((4-methoxybenzyl)(methyl)amino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 15, 162 mg, 0.27 mmol) in MeOH (10 mL) was added Pd / C (10 wt%, 280 mg, 0.26 mmol). The suspension was stirred for 4 h at room temperature under a hydrogen atmosphere (balloon, flask was evacuated and refilled with hydrogen three times). The reaction mixture was diluted with MeOH, filtered through diatomaceous earth, and the filtrate was concentrated to dryness. The resulting residue was dissolved in 6M aq. HCl (10 mL) and heated to 100° C. for 2 h. The reaction mixture was cooled to room temperature, diluted with HO (10 mL) and washed with DCM (2x15 mL). The aqueous layer was concentrated under reduced pressure and the resulting residue was purified by reverse phase chromatography (RediSep Rf Gold® C18, 0-30% acetonitrile in water) to give (2S,3R)-2-amino-6-borono-3-((methylamino)methyl)hexanoic acid (Example 4, 33 mg, 43% yield) as a white solid. The resulting material was a 6.1:1 mixture of the title product and the C3 diastereomer. 1 H NMR(300MHz,D2O)δ 0.73-0.81(2H,m),1.35-1.55(4H,m),2.27-2.45(1H,m),2.74(3H,s),3.05-3.22(1. 82H,m), 3.29-3.37(0.12H,m),3.85-3.93(0.81H,m),3.99-4.03(0.12H,m) + ) [M+H] + =219.

[0158] Example 5: (2S,3R)-2-Amino-6-borono-3-((dimethylamino)methyl)hexanoic acid [ka]

[0159] Intermediate 16: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((dimethylamino)methyl)hex-5-enoate A solution of oxalyl chloride (2M in DCM, 2.54 mL, 5.08 mmol) was placed in an oven-dried flask, diluted with DCM (10 mL) and cooled to -78 °C under an atmosphere of N2. DMSO (0.54 mL, 7.6 mmol) was added dropwise and the reaction mixture was stirred at -78 °C for 10 min. (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(hydroxymethyl)hex-5-enoate (Intermediate 4, 888 mg, 2.54 mmol) was added slowly as a solution in DCM (10 mL) and the reaction was stirred at -78 °C for 30 min. N,N-Diisopropylethylamine (0.50 mL, 2.9 mmol) was added and the reaction was stirred at -78 °C for 1 h and then warmed to 0 °C with stirring for an additional 15 min. The reaction mixture was quenched with saturated aqueous NaHCO3 (20 mL) and diluted with DCM (40 mL). The layers were separated and the aq. layer was extracted with DCM (2x20 mL). The combined organics were dried over anhydrous Na2SO4, filtered and concentrated to dryness. A portion of the crude aldehyde (294 mg, 0.847 mmol) was dissolved in DCM (20 mL) and a solution of dimethylamine (2M in THF, 1.70 mL, 3.40 mmol) was added, followed by sodium triacetoxyborohydride (448 mg, 2.12 mmol) and acetic acid (0.048 mL, 0.85 mmol). The resulting suspension was stirred at room temperature for 15 h. The reaction mixture was diluted with DCM (50 mL) and saturated aqueous NaHCO3 (10 mL) and the layers were separated. The aq. layer was extracted with DCM (2x10 mL). The combined organics were dried over Na2SO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((dimethylamino)methyl)hex-5-enoate (Intermediate 16, 253 mg, 79% yield) as a colorless oil. m / z: (ES + ) [M+H] + =377.

[0160] Intermediate 17: (4R,5S)-5-(benzyloxycarbonylamino)-6-tert-butoxy-4-((dimethylamino)methyl)-6-oxohexylboronic acid Bis(1,5-cyclooctadiene)diiridium(I) dichloride (16 mg, 0.025 mmol) and bis(diphenylphosphino)methane (26 mg, 0.067 mmol) were placed in an oven-dried round-bottom flask. The flask was sealed and purged with N2. The solid was dissolved in DCM (3 mL) and to the solution was slowly added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.22 mL, 1.5 mmol). The reaction was stirred at room temperature for 10 minutes. To the reaction was added (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((dimethylamino)methyl)hex-5-enoate (Intermediate 16, 253 mg, 0.672 mmol) as a solution in DCM (3 mL) and the reaction mixture was mixed overnight. The reaction mixture was cooled to 0° C. and quenched with MeOH (2 mL) and water (10 mL). The layers were separated and the aqueous layer was extracted with DCM (2×10 mL). The combined organics were dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (4R,5S)-5-(benzyloxycarbonylamino)-6-tert-butoxy-4-((dimethylamino)methyl)-6-oxohexylboronic acid (Intermediate 17, 223 mg, 79% yield). m / z: (ES + ) [M+H] + =422.

[0161] Example 5: (2S,3R)-2-Amino-6-borono-3-((dimethylamino)methyl)hexanoic acid (4R,5S)-5-(benzyloxycarbonylamino)-6-tert-butoxy-4-((dimethylamino)methyl)-6-oxyhexylboronic acid (Intermediate 17, 223 mg, 0.528 mmol) was dissolved in 6M aq. HCl (15 mL) and the solution was heated to 100° C. for 20 h. The reaction mixture was cooled to room temperature and the solids were removed by filtration and washed with water. The aqueous filtrate was washed with DCM (3×20 mL) and concentrated under reduced pressure. The resulting residue was dissolved in MeOH (3 mL) and purified by ion exchange chromatography (PoraPak Rxn CX 20 cc column). The desired product was eluted from the column using a 5% ammonia in MeOH solution (20 mL). The product-containing fractions were collected and concentrated to give (2S,3R)-2-amino-6-borono-3-((dimethylamino)methyl)hexanoic acid (Example 5, 68 mg, 56% yield) as a white solid. The resulting material was a 10:1 mixture of the title compound and the C3 diastereomer. 1 H NMR(300MHz,D2O)δ 0.77(2H,m),1.25-1.48(4H,m),2.25(1H,m),2.69(6H,s),2.85-3.05(2H,m),3.62(1H,d);m / z:(ES + ) [M+H] + =233.

[0162] Example 6: (2S,3R)-2-Amino-6-borono-3-(guanidinomethyl)hexanoic acid dihydrochloride [ka]

[0163] Intermediate 18: tert-Butyl (2S,3R)-2-(((benzyloxy)carbonyl)amino)-3-(((2,2,10,10-tetramethyl-4,8-dioxo-3,9-dioxa-5,7-diazaundecan-6-ylidene)amino)methyl)hex-5-enoate (2S,3S)-tert-Butyl 2-(benzyloxycarbonylamino)-3-(hydroxymethyl)hex-5-enoate (Intermediate 4, 500 mg, 1.43 mmol) was dissolved in anhydrous toluene (14 mL). Triphenylphosphine (826 mg, 3.15 mmol) and 1,3-bis(tert-butoxycarbonyl)guanidine (742 mg, 2.86 mmol) were added and the solution was cooled to 0° C. DIAD (637 mg, 3.15 mmol) was added dropwise and the reaction mixture was allowed to warm to room temperature and then further heated to 100° C. for 30 min. The reaction mixture was cooled to room temperature and washed with water (5 mL). The organic layer was dried over Na2SO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give tert-butyl (2S,3R)-2-(((benzyloxy)carbonyl)amino)-3-(((2,2,10,10-tetramethyl-4,8-dioxo-3,9-dioxa-5,7-diazaundecan-6-ylidene)amino)methyl)hex-5-enoate (Intermediate 18, 300 mg, 35.5%) as a sticky oil. 1 H NMR(300MHz,CDCl3)δ 1.40(9H,s),1.49-1.61(18H,m),2.11-2.50(3H,m),3.75-4.05(2H,m),4.21(1H,br d),4.97-5.17(4H,m),5.67-5.91(1H,m),6.20(1H,br s),7.27-7.40(5H,m),9.01-9.60(2H,m);m / z:(ES + ) [M+H] + =591.

[0164] Intermediate 19: tert-Butyl (2S,3R)-2-(((benzyloxy)carbonyl)amino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(((2,2,10,10-tetramethyl-4,8-dioxo-3,9-dioxa-5,7-diazaundecan-6-ylidene)amino)methyl)hexanoate Bis(1,5-cyclooctadiene)diiridium(I) dichloride (13 mg, 0.019 mmol) and bis(diphenylphosphino)methane (16 mg, 0.042 mmol) were placed in an oven-dried round-bottom flask. The flask was sealed and purged with N2. The solid was dissolved in DCM (8 mL) and to the solution was slowly added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.18 mL, 1.3 mmol). The reaction was stirred at room temperature for 10 min. To the reaction was added tert-butyl (2S,3R)-2-(((benzyloxy)carbonyl)amino)-3-(((2,2,10,10-tetramethyl-4,8-dioxo-3,9-dioxa-5,7-diazaundecan-6-ylidene)amino)methyl)hex-5-enoate (Intermediate 18, 300 mg, 0.51 mmol) as a solution in DCM (2 mL) and the reaction was stirred at room temperature for 24 h. The reaction mixture was concentrated to dryness and directly purified by silica gel chromatography (hexanes / EtOAc) to give tert-butyl (2S,3R)-2-(((benzyloxy)carbonyl)amino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(((2,2,10,10-tetramethyl-4,8-dioxo-3,9-dioxa-5,7-diazaundecan-6-ylidene)amino)methyl)hexanoate (Intermediate 19, 190 mg, 52% yield) as a colorless oil. 1 H NMR(300MHz,CDCl3)δ 0.75(2H,t),1.12-1.24(14H,m),1.33-1.42(10H,m),1.46(9H,s),1.48-1.55(10H,m),2.23-2.42(1H,m),3.54-3.87(1H,m) m / z:(ES + ) [M+H] + =719.

[0165] Example 6: (2S,3R)-2-Amino-6-borono-3-(guanidinomethyl)hexanoic acid dihydrochloride tert-Butyl (2S,3R)-2-(((benzyloxy)carbonyl)amino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(((2,2,10,10-tetramethyl-4,8-dioxo-3,9-dioxa-5,7-diazaundecan-6-ylidene)amino)methyl)hexanoate (Intermediate 19, 45 mg, 0.063 mmol) was dissolved in 6M aq. HCl (2.08 mL, 12.5 mmol) and the reaction mixture was heated to 90° C. for 30 min. The reaction was cooled to 70° C. and stirred for an additional 1 h. The reaction mixture was cooled to room temperature, diluted with water (2 mL) and extracted with EtOAc (3×1 mL). The aqueous layer was lyophilized to give (2S,3R)-2-amino-6-borono-3(guanidinomethyl)hexanoic acid dihydrochloride (Example 6, 10 mg, 50% yield) as a white solid. 1 H NMR(300MHz,D2O)δ 0.80(2H,br d),1.37-1.62(4H,m),2.41(1H,br d),3.34(2H,dd),4.09(1H,d);m / z:(ES + ) [M+H] + =247.

[0166] Example 7: (2S,3R)-2-Amino-6-borono-3-(ureidomethyl)hexanoic acid [ka]

[0167] Intermediate 20: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(ureidomethyl)hexanoate To a solution of (2S,3R)-tert-butyl 3-(azidomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 8, 485 mg, 1.04 mmol) and isocyanatotrimethylsilane (0.35 mL, 2.6 mmol) in EtOAc (40 mL) was added Pd / C (10 wt%, 220 mg, 0.21 mmol). The mixture was evacuated and backfilled with nitrogen three times, then evacuated and backfilled with hydrogen. The suspension was stirred for 3 h at room temperature under a hydrogen atmosphere. An additional portion of isocyanatotrimethylsilane (0.15 mL, 1.1 mmol) was added and the suspension was stirred for an additional 20 min at room temperature. The reaction mixture was diluted with DCM, filtered through diatomaceous earth, and the filtrate was concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(ureidomethyl)hexanoate (Intermediate 20, 242 mg, 48% yield) as a white solid. m / z: (ES + ) [M+H] + =486.

[0168] Example 7: (2S,3R)-2-Amino-6-borono-3-(ureidomethyl)hexanoic acid To a stirred solution of (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(ureidomethyl)hexanoate (Intermediate 20, 242 mg, 0.466 mmol) in DCM (6 mL) was slowly added trifluoroacetic acid (6.00 mL, 77.9 mmol) and the reaction was stirred at room temperature for 6 h. The solution was concentrated under reduced pressure and the resulting residue was dissolved in 1 M aq. HCl (5 mL) and Et2O (5 mL). Phenylboronic acid (117 mg, 0.96 mmol) was added and the clear biphasic solution was stirred at room temperature for 16 h. The reaction mixture was diluted with Et2O and water and the layers were separated. The aqueous layer was washed with Et2O (2 x 30 mL) and the aqueous layer was lyophilized. The crude material was purified by reverse phase chromatography (RediSep Rf Gold® C18, 0-50% acetonitrile in water) to give (2S,3R)-2-amino-6-borono-3-(ureidomethyl)hexanoic acid (Example 7, 5.0 mg, 4% yield) as a white solid. 1 H NMR(300MHz,D2O)δ 0.77-0.82(2H,m),1.24-1.49(4H,m),2.11-2.20(1H,m),3.07-3.22(2H,m),3.71(1H,d);m / z:(ES + ) [M+H] + =248.

[0169] Example 8: (2S,3R)-2-amino-3-(((S)-2-amino-3-methylbutanamido)methyl)-6-boronohexanoic acid [ka]

[0170] Intermediate 21: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((N-(tert-butoxycarbonyl)-2-(trimethylsilyl)ethylsulfonamido)methyl)hex-5-enoate (2S,3S)-tert-Butyl 2-(benzyloxycarbonylamino)-3-(hydroxymethyl)hex-5-enoate (Intermediate 4, 938 mg, 2.68 mmol) and tert-butyl ((2-(trimethylsilyl)ethyl)sulfonyl)carbamate (1.1 g, 3.9 mmol) were dissolved in THF (10 mL) and cooled to 0° C. Triphenylphosphine (1.06 mg, 4.03 mmol) and DIAD (1.1 mL, 5.7 mmol) were added and the reaction was stirred for 16 h with slow warming to room temperature. The reaction was quenched with saturated aqueous sodium bicarbonate (10 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (2×10 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to afford (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((N-(tert-butoxycarbonyl)-2-(trimethylsilyl)ethylsulfonamido)methyl)hex-5-enoate (Intermediate 21, 1.56 g, 95%) as a colorless gum. 1 H NMR(300MHz,CDCl3)δ 0.04(9H,s),0.81-0.99(2H,m),1.46(9H,s),1.49(9H,m),2.05-2.29(2H ,m),2.44-2.58(1H,m),3.34-3.54(2H,m),3.55-3.81(2H,m),4.35(1H,br m / z:(ES + )[M+NH4] + =630.

[0171] Intermediate 22: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)hex-5-enoate (2S,3R)-tert-Butyl 2-(benzyloxycarbonylamino)-3-((N-(tert-butoxycarbonyl)-2-(trimethylsilyl)ethylsulfonamido)methyl)hex-5-enoate (Intermediate 21, 1.40 g, 2.28 mmol) was dissolved in a solution of TBAF (1 M in THF, 12.0 mL, 12.0 mmol) and the resulting solution was stirred at room temperature for 16 h. The reaction was diluted with EtO (40 mL) and subsequently washed with water (3×25 mL) and saturated aqueous sodium bicarbonate (20 mL). The organic layer was dried over MgSO, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to afford (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)hex-5-enoate (Intermediate 22, 576 mg, 56% yield) as a colorless oil. 1 H NMR(300MHz,CDCl3)δ 1.43(9H,s),1.44(9H,s),1.74-1.88(1H,m),1.89-2.00(1H,m),2.17-2.30(1H,m),2.41- 2.60(1H,m),3.38-3.62(1H,m),4.46(1H,dd),4.98-5.08(2H,m),5.09(2H,s),5.40(1H,br d),5.52-5.88(2H,m),7.27-7.38(5H,m);m / z:(ES + ) [M+H] + =449.

[0172] Intermediate 23: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate Bis(1,5-cyclooctadiene)diiridium(I) dichloride (13 mg, 0.065 mmol) and bis(diphenylphosphino)methane (49 mg, 0.13 mmol) were placed in an oven-dried round-bottom flask. The flask was sealed and purged with N2. The solid was dissolved in DCM (4 mL) and to the solution was slowly added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.50 mL, 3.5 mmol). The reaction was stirred at room temperature for 10 min. To the reaction was added (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)hex-5-enoate (Intermediate 22, 576 mg, 1.28 mmol) as a solution in DCM (3 mL) and the reaction was stirred at room temperature for 3 days. The reaction mixture was cooled to 0° C. and quenched with MeOH (2 mL) and water (15 mL). The layers were separated and the aqueous layer was extracted with DCM (2×10 mL). The combined organics were dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to afford (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 23, 424 mg, 57% yield) as a pale yellow gum. 1 H NMR(300MHz,CDCl3)δ 0.57-0.81(2H,m),0.94-1.15(2H,m),1.19(12H,s),1.28-1.59(20H,m),2.05-2.23( 1H,m),2.40-2.57(1H,m),3.39-3.60(1H,m),4.43(1H,dd),5.08(2H,s),5.41(1H,br d),5.53-5.78(1H,m),7.27-7.38(5H,m);m / z:(ES + ) [M+H] + =577.

[0173] Intermediate 24: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)-3-methylbutanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 23, 424 mg, 0.740 mmol) in dioxane (1.5 mL) at 0° C. was added a solution of HCl (4 M in dioxane, 1.5 mL, 6.0 mmol). The reaction was stirred for 6 h with slow warming to room temperature. The solution was concentrated to give a yellow gum which was used directly without purification. In a separate flask, to a solution of Boc-L-Val-OH (354 mg, 1.63 mmol) in DMF (3.5 mL) was added HATU (619 mg, 1.63 mmol) and the reaction was stirred for 10 min at room temperature. The crude amine was dissolved in DMF (3.5 mL) and placed in a separate reaction flask. N,N-diisopropylethylamine (0.45 mL, 2.6 mmol) was added and the reaction was stirred at room temperature for 16 h. The reaction mixture was diluted with EtOAc (15 mL) and washed with 1 M aqHCl (60 mL) and 5% aqueous lithium chloride (10 mL). The organic layer was dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (DCM / MeOH) to afford (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)-3-methylbutanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 24, 476 mg, 95% yield) as a pale yellow gum. 1H NMR(300MHz,CDCl3)δ 0.59-0.82(2H,m),0.87-0.98(6H,m),1.18(12H,s),1.28-1.55(22H,m),2.07-2.24(2H,m),2.31-2.51( 1H,m),3.38-3.54(1H,m),3.74-3.89(1H,m),3.89-4.06(1H,m),4.35(1H,dd),5.08(2H,s),5.50(1H,br d),6.92(1H,br s),7.26-7.37(5H,m);m / z:(ES - )[M+HCOO - ] - =720.

[0174] Example 8: (2S,3R)-2-amino-3-(((S)-2-amino-3-methylbutanamido)methyl)-6-boronohexanoic acid (2S,3R)-tert-Butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)-3-methylbutanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 24, 476 mg, 0.700 mmol) was dissolved in a solution of HBr (33 wt% in AcOH, 3.5 mL, 21 mmol) and the reaction was stirred at room temperature for 20 min. The reaction was diluted with Et2O (10 mL) and concentrated. This process was repeated two more times. The resulting residue was dissolved in 2 M aq. HCl (5 mL) and Et2O (5 mL). Phenylboronic acid (172 mg, 1.41 mmol) was added and the clear biphasic solution was stirred at room temperature for 2 h. The layers were separated and the aqueous layer was washed with Et2O (3 x 10 mL) and lyophilized. The resulting solid was dissolved in MeOH (1 mL) and purified by ion exchange chromatography (HyperSep Retain CX column). The desired product was eluted from the column using a 5% ammonia solution in MeOH (15 mL). The resulting material was further purified by reverse phase chromatography (RediSep Rf Gold® C18, 0-100% acetonitrile in water) to give (2S,3R)-2-amino-3-(((S)-2-amino-3-methylbutanamido)methyl)-6-boronohexanoic acid (Example 8, 46 mg, 21% yield) as a white solid. 1 H NMR(300MHz,D2O)δ m / z:(ES - )[MH] - =302.

[0175] Example 9: (2S,3R)-2-amino-3-(((S)-2-aminobutanamido)methyl)-6-boronohexanoic acid [ka]

[0176] Intermediate 25: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)butanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 23, 1.27 g, 2.20 mmol) in dioxane (1.5 mL) at 0° C. was added a solution of HCl (4 M in dioxane, 4.40 mL, 17.6 mmol). The reaction was stirred for 4.5 h with slow warming to room temperature. The solution was concentrated to give a yellow gum which was used directly without purification. In a separate flask, to a solution of Boc-Abu-OH (335 mg, 1.65 mmol) in DMF (5 mL) was added HATU (619 mg, 1.63 mmol) and the reaction was stirred for 10 min at room temperature. The crude amine from the previous work was split into two equal portions (assuming 524 mg, 1.10 mmol) and one portion was dissolved in DMF (5 mL) and placed in a separate reaction flask. N,N-diisopropylethylamine (0.60 mL, 3.4 mmol) was added and the reaction was stirred at room temperature for 2 h. The reaction mixture was diluted with EtOAc (15 mL) and washed with 1 M aq. HCl (60 mL) and 5% aqueous lithium chloride (10 mL). The organic layer was dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (DCM / MeOH) to afford (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)butanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 25, 516 mg, 71% yield) as a colorless gum. 1H NMR(300MHz,CDCl3)δ 0.58-0.82(2H,m),0.93(3H,t),1.19(12H,s),1.38-1.45(22H,m),1.60-1.76(1H,m),1.77-1.97(2H,m),2.10-2.26( 1H,m),2.40(1H,dt),3.78-3.90(1H,m),4.03-4.16(1H,m),4.34(1H,dd),5.08(2H,s),5.15-5.24(1H,m),5.48(1H,br d),7.27-7.39(5H,m);m / z:(ES + ) [M+H] + =662.

[0177] Example 9: (2S,3R)-2-amino-3-(((S)-2-aminobutanamido)methyl)-6-boronohexanoic acid (2S,3R)-tert-Butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)butanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 25, 516 mg, 0.780 mmol) was dissolved in a solution of HBr (33 wt% in AcOH, 4.0 mL, 24 mmol) and the reaction was stirred at room temperature for 20 min. The reaction was diluted with Et2O (10 mL) and concentrated. This process was repeated two more times. The resulting residue was dissolved in 2 M aq. HCl (5 mL) and Et2O (7 mL). Phenylboronic acid (190 mg, 1.6 mmol) was added and the clear biphasic solution was stirred at room temperature for 2 h. The layers were separated and the aqueous layer was washed with Et2O (3 x 10 mL) and lyophilized. The resulting solid was dissolved in MeOH (1 mL) and purified by ion exchange chromatography (Silicycle SPE-R51230B-20X column). A 5% ammonia solution in MeOH (15 mL) was used to elute the desired product from the column. The resulting material was further purified by reverse phase chromatography (RediSep Rf Gold® C18, 0-100% acetonitrile in water) to give (2S,3R)-2-amino-3-(((S)-2-aminobutanamido)methyl)-6-boronohexanoic acid (Example 9, 101 mg, 45% yield) as a white solid. 1 H NMR(300MHz,D2O)δ 0.66-0.85(2H,m),0.92(3H,t),1.24-1.55(4H,m),1.65-1.83(2H,m),2 .16-2.31(1H,m),3.24-3.39(2H,m),3.56(1H,t),3.65(1H,d);m / z:(ES + ) [M+H] + =290.

[0178] Example 10: (2S,3R)-2-amino-3-(((S)-2-aminopropanamido)methyl)-6-boronohexanoic acid [ka]

[0179] Intermediate 26: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)propanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 23, 375 mg, 0.650 mmol) in dioxane (2 mL) at 0° C. was added a solution of HCl (4M in dioxane, 0.34 mL, 1.4 mmol) and the reaction was stirred for 50 min at 0° C. An additional portion of HCl (4M in dioxane, 0.34 mL, 1.4 mmol) was added and the reaction was stirred for an additional hour. An additional portion of HCl (4M in dioxane, 0.70 mL, 2.7 mmol) was added and the reaction was stirred for 1 hour and then placed in a −20° C. freezer for 16 hours. The reaction was allowed to warm to room temperature and stirred for 20 min. The solution was concentrated to a yellow gum that was used directly without purification. In a separate flask, HATU (544 mg, 1.43 mmol) was added to a solution of Boc-Ala-OH (271 mg, 1.43 mmol) in DMF (3 mL) and the reaction was stirred for 10 min at room temperature. The crude amine was dissolved in DMF (3 mL) and placed in the separate reaction flask. N,N-diisopropylethylamine (0.38 mL, 2.2 mmol) was added and the reaction was stirred for 2 h at room temperature. The reaction mixture was diluted with EtOAc (15 mL) and washed with 1 M aqHCl (60 mL) and 5% aqueous lithium chloride (30 mL). The organic layer was dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (DCM / MeOH) to afford (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)propanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 26, 268 mg, 64% yield) as a pale yellow gum. 1H NMR(300MHz,CDCl3)δ 0.55-0.84(2H,m),0.96-1.27(14H,m),1.30-1.52(23H,m),2.07-2.27(1H,m),2.34-2.63(1H,m),2.74-2.99(1H ,m),3.61-3.93(1H,m),3.99-4.23(1H,m),4.23-4.42(1H,m),4.90-5.24(3H,m),5.41-5.60(1H,m),7.33(5H,br s);m / z:(ES + ) [M+H] + =648.

[0180] Example 10: (2S,3R)-2-amino-3-(((S)-2-aminopropanamido)methyl)-6-boronohexanoic acid (2S,3R)-tert-Butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)propanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 26, 268 mg, 0.410 mmol) was dissolved in a solution of HBr (33 wt% in AcOH, 2.0 mL, 12 mmol) and the reaction was stirred at room temperature for 20 min. The reaction was diluted with Et2O (5 mL) and concentrated. This process was repeated two more times. The resulting residue was dissolved in 2 M aq. HCl (2.5 mL) and Et2O (5 mL). Phenylboronic acid (100 mg, 0.83 mmol) was added and the clear biphasic solution was stirred at room temperature for 2 h. The layers were separated and the aqueous layer was washed with Et2O (3 x 10 mL) and lyophilized. The resulting solid was dissolved in MeOH (1 mL) and purified by ion exchange chromatography (HyperSep Retain CX column). A 5% ammonia solution in MeOH (15 mL) was used to elute the desired product from the column. The resulting material was further purified by reverse phase chromatography (RediSep Rf Gold® C18, 0-100% acetonitrile in water) to give (2S,3R)-2-amino-3-(((S)-2-aminopropanamido)methyl)-6-boronohexanoic acid (Example 10, 45 mg, 39% yield) as a white solid. 1 H NMR(300MHz,D2O)δ 0.63-0.84(2H,m),1.20-1.55(7H,m),2.14-2.25(1H,m),3.20-3.36(2H,m),3.62(1H,d),3.74(1H,q);m / z(ES + ) [M+H] + =276.

[0181] Example 11: (2S,3R)-3-(acetamidomethyl)-2-amino-6-boronohexanoic acid [ka]

[0182] Intermediate 27: (2S,3R)-tert-butyl 3-(acetamidomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 23, 1.27 g, 2.20 mmol) in dioxane (1.5 mL) at 0° C. was added a solution of HCl (4 M in dioxane, 4.40 mL, 17.6 mmol). The reaction was stirred for 4.5 h with slow warming to room temperature. The solution was concentrated to give a yellow gum which was used directly without purification. The crude amine was split into two equal portions (assumed 524 mg, 1.10 mmol) and one portion was dissolved in DMF (5 mL). Triethylamine (0.40 mL, 2.9 mmol) was added and the reaction was stirred for 10 min at room temperature. Acetyl chloride (0.10 mL, 1.4 mmol) was added and the reaction was stirred for an additional 2 h. The reaction was quenched with water (15 mL) and diluted with DCM (20 mL). The layers were separated and the aqueous layer was extracted with DCM (2×10 mL). The combined organic layers were washed with saturated aqueous sodium bicarbonate (20 mL) then dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (DCM / MeOH) to give (2S,3R)-tert-butyl 3-(acetamidomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 27, 538 mg, 94% yield) as a colorless oil. 1H NMR(300MHz,CDCl3)δ 0.55-0.81(2H,m),1.19(12H,s),1.26-1.59(13H,m),1.98(3H,s),2.07-2.20(1 H,m),2.33-2.45(1H,m),3.84(1H,ddd),4.36(1H,dd),5.08(2H,s),5.49(1H,br d),6.76-6.90(1H,m),7.26-7.40(5H,m);m / z:(ES + ) [M+H] + =519.

[0183] Example 11: (2S,3R)-3-(acetamidomethyl)-2-amino-6-boronohexanoic acid (2S,3R)-tert-Butyl 3-(acetamidomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 27, 538 mg, 1.04 mmol) was dissolved in a solution of HBr (33 wt% in AcOH, 5.0 mL, 30 mmol) and the reaction was stirred at room temperature for 20 min. The reaction was diluted with Et2O (10 mL) and concentrated. This process was repeated two more times. The resulting residue was dissolved in 2 M aq. HCl (7 mL) and Et2O (7 mL). Phenylboronic acid (253 mg, 2.08 mmol) was added and the clear biphasic solution was stirred at room temperature for 2 h. The layers were separated and the aqueous layer was washed with Et2O (3 x 10 mL) and lyophilized. The resulting solid was dissolved in MeOH (1 mL) and purified by ion exchange chromatography (Silicycle SPE-R51230B-20X column). A 5% ammonia solution in MeOH (15 mL) was used to elute the desired product from the column. The resulting material was further purified by reverse phase chromatography (RediSep Rf Gold® C18, 0-100% acetonitrile in water) to give (2S,3R)-3-(acetamidomethyl)-2-amino-6-boronohexanoic acid (Example 11, 84 mg, 33% yield) as a white solid. 1H NMR(300MHz,D2O)δ 0.67-0.86(2H,m),1.26-1.59(4H,m),2.01(3H,s),2.14-2.31(1H,m),3.15-3.39(2H,m),3.71(1H,d);m / z:(ES + ) [M+H] + =247.

[0184] Example 12: (2S,3R)-3-(aminomethyl)-6-borono-2-(methylamino)hexanoic acid [ka]

[0185] Intermediate 28: (2S,3R)-tert-butyl 3-(azidomethyl)-2-((benzyloxycarbonyl)(methyl)amino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (2S,3R)-tert-Butyl 3-(azidomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 8, 155 mg, 0.310 mmol) was dissolved in DMF (2 mL) and the solution was cooled to 0° C. Sodium hydride (60% wt. dispersion in oil, 15 mg, 0.37 mmol) was added and the reaction was allowed to warm to room temperature and stirred for 15 min. Iodomethane (0.05 mL, 0.8 mmol) was added and the reaction was allowed to stir at room temperature for 16 h. The reaction mixture was diluted with water (15 ml) and extracted with Et2O (3×15 mL). The combined organics were washed with 5% aqueous lithium chloride (10 mL), dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to afford (2S,3R)-tert-butyl 3-(azidomethyl)-2-((benzyloxycarbonyl)(methyl)amino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 28, 109 mg, 68% yield) as a colorless oil and a 55:45 mixture of rotamers.1 H NMR(300MHz,CDCl3)δ 0.66-0.82(2H,m),1.21(12H,s),1.23-1.37(3H,m),1.40(5H,s),1.42(4H,s)1.4 6-1.53(1H,m),2.06-2.22(1H,m),2.86(3H,s),3.37-3.55(2H,m),4.50(0.55H,br d),4.65(0.45H,br d),4.95-5.30(2H,m),7.26-7.41(5H,m);m / z:(ES + )[M+NH4] + =534.

[0186] Example 12: (2S,3R)-3-(aminomethyl)-6-borono-2-(methylamino)hexanoic acid To a solution of (2S,3R)-tert-butyl 3-(azidomethyl)-2-((benzyloxycarbonyl)(methyl)amino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 28, 109 mg, 0.210 mmol) in EtOAc (2 mL) was added Pd / C (10 wt%, 22 mg, 0.020 mmol) and di-tert-butyl-dicarbonate (115 mg, 0.530 mmol). The flask was equipped with a balloon of H2 and the suspension was stirred at room temperature for 16 h. The reaction mixture was filtered through diatomaceous earth and rinsed with EtOAc. The filtrate was concentrated to dryness and dissolved in DCM (3 mL). A solution of HBr (33% in AcOH, 0.50 mL, 3.0 mmol) was added and the reaction was stirred at room temperature for 20 min. The reaction was diluted with Et2O (5 mL) and concentrated. This process was repeated two more times. The resulting residue was dissolved in 2M aq. HCl (2 mL) and Et2O (2 mL). Phenylboronic acid (51 mg, 0.42 mmol) was added and the clear biphasic solution was stirred at room temperature for 2 h. The layers were separated and the aqueous layer was washed with Et2O (3 x 10 mL) and lyophilized. The resulting solid was purified by reverse phase chromatography (RediSep Rf Gold® C18, 0-100% acetonitrile in water) to give a dark yellow solid. The resulting material was redissolved in MeOH (1 mL) and loaded onto a pre-equilibrated Hypersep Retain CX (2 g) ion exchange column. The resin was washed with MeOH (15 mL) followed by a 5% solution of NH3 in MeOH (15 mL) to elute the product. The product-containing fractions were concentrated to give a colorless residue, which was further purified by reverse-phase chromatography (RediSep Rf Gold® C18Aq, 0-100% MeCN in water) to give (2S,3R)-3-(aminomethyl)-6-borono-2-(methylamino)hexanoic acid (Example 12, 15 mg, 33%) as a white solid. 1H NMR(300MHz,D2O)δ 0.68-0.91(2H,m),1.34-1.59(4H,m),2.11-2.26(1H,m),2.60(3H,s),3.07(2H,qd),3.51(1H,d);m / z:(ES + ) [M-H2O+H] + =201.

[0187] Example 13: (2S,3R)-2-((S)-2-amino-3-methylbutanamido)-3-(aminomethyl)-6-boronohexanoic acid [ka]

[0188] Intermediate 29: (2S,3R)-tert-butyl 2-((S)-2-(tert-butoxycarbonylamino)-3-methylbutanamido)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 23, 950 mg, 1.65 mmol) in EtOAc (12 mL) was added Pd / C (10 wt%, 180 mg, 0.16 mmol). The flask was equipped with a balloon of H2 and the suspension was stirred at room temperature for 16 h. The reaction mixture was filtered through diatomaceous earth and rinsed with EtOAc (50 mL). The filtrate was concentrated to give a pale yellow oil that was used directly without further purification. In a separate flask, to a solution of Boc-L-Val-OH (210 mg, 0.95 mmol) in DMF (4 mL) was added HATU (363 mg, 0.95 mmol) and the reaction was stirred at room temperature for 10 min. The crude amine from the previous work was split into two equal portions (assumed 364 mg, 0.825 mmol) and one portion was dissolved in DMF (5 mL) and placed in the separate reaction flask. N,N-Diisopropylethylamine (0.35 mL, 2.0 mmol) was added and the reaction was stirred at room temperature for 2 h. The reaction mixture was diluted with EtOAc (15 mL) and washed with 1 M aq. HCl (80 mL) and saturated aqueous sodium chloride (20 mL). The organic layer was dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (DCM / MeOH) to afford (2S,3R)-tert-butyl 2-((S)-2-(tert-butoxycarbonylamino)-3-methylbutanamido)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 29, 400 mg, 72% yield) as a colorless gum. 1H NMR(300MHz,DMSO-d6)δ 0.55-0.69(2H,m),0.84(6H,dd),1.16(12H,s),1.31-1.43(31H,m),1.83-2.07(2H,m),2.55-2.66(1H,m),2.98-3.13(1H,m),3.83(1H,br m / z:(ES - )[M+HCOO - ] - =686.

[0189] Example 13: (2S,3R)-2-((S)-2-amino-3-methylbutanamido)-3-(aminomethyl)-6-boronohexanoic acid To a solution of (2S,3R)-tert-butyl 2-((S)-2-(tert-butoxycarbonylamino)-3-methylbutanamido)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 29, 200 mg, 0.31 mmol) in DCM (4 mL) was added a solution of HBr (33 wt% in AcOH, 0.75 mL, 4.6 mmol) and the reaction was stirred at room temperature for 1 h. The reaction was diluted with Et2O (5 mL) and concentrated. This process was repeated two more times. The resulting residue was dissolved in 1 M aq. HCl (7 mL) and Et2O (5 mL). Phenylboronic acid (114 mg, 0.940 mmol) was added and the clear biphasic solution was stirred for 2 h at room temperature. The layers were separated and the aqueous layer was washed with Et2O (3 x 10 mL) and lyophilized. The resulting solid was dissolved in MeOH (1 mL) and purified by ion exchange chromatography (PoraPak Rxn CX 20 cc column). A 5% ammonia solution in MeOH (15 mL) was used to elute the desired product from the column. The resulting material was further purified by reverse phase chromatography (RediSep Rf Gold® C18, 0-100% acetonitrile in water) to give (2S,3R)-2-((S)-2-amino-3-methylbutanamido)-3-(aminomethyl)-6-boronohexanoic acid (Example 13, 57 mg, 61% yield) as a white solid. 1 H NMR(300MHz,D2O)δ 0.67-0.85(2H,m),0.97(6H,dd),1.16-1.56(4H,m),1.95-2.15(1H, sextet),2 .38(1H,td),2.76(1H,dd),3.14(1H,dd),3.47(1H,d),4.41(1H,d);m / z:(ES + ) [M+H] + =304.

[0190] Example 14: (2S,3R)-3-(aminomethyl)-2-((S)-2-aminopropanamido)-6-boronohexanoic acid [ka]

[0191] Intermediate 30: (2S,3R)-tert-butyl 3-((tert-butoxycarbonylamino)methyl)-2-((S)-2-(tert-butoxycarbonylamino)propanamido)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 23, 950 mg, 1.65 mmol) in EtOAc (12 mL) was added Pd / C (10 wt%, 180 mg, 0.16 mmol). The flask was equipped with a balloon of H2 and the suspension was stirred at room temperature for 16 h. The reaction mixture was filtered through diatomaceous earth and rinsed with EtOAc (50 mL). The filtrate was concentrated to give a pale yellow oil that was used directly without further purification. In a separate flask, HATU (363 mg, 0.95 mmol) was added to a solution of Boc-Ala-OH (180 mg, 0.95 mmol) in DMF (4 mL) and the reaction was stirred for 10 min at room temperature. The crude amine from the previous work was split into two equal portions (assuming 364 mg, 0.825 mmol) and one portion was dissolved in DMF (5 mL) and placed in the separate reaction flask. N,N-Diisopropylethylamine (0.35 mL, 2.0 mmol) was added and the reaction was stirred for 16 h at room temperature. The reaction mixture was diluted with EtOAc (15 mL) and washed with 1 M aq. HCl (80 mL) and saturated aqueous sodium chloride (20 mL). The organic layer was dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (DCM / MeOH) to afford (2S,3R)-tert-butyl 3-((tert-butoxycarbonylamino)methyl)-2-((S)-2-(tert-butoxycarbonylamino)propanamido)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 30, 191 mg, 36% yield) as a colorless oil. 1H NMR(300MHz,CDCl3)δ 0.54-0.82(2H,m),0.84-1.12(2H,m),1.19(12H,s),1.29-1.38(4H,m),1.38-1.58(28H,m),2.07-2.24(1H,m),2.25-2 .44(1H,m),3.29-3.61(1H,m),4.05-4.19(1H,m),4.55-4.71(1H,m),4.86-5.14(1H,m),5.60-6.01(1H,m),6.66(1H,br d);m / z:(ES + ) [M+H] + =614.

[0192] Example 14: (2S,3R)-3-(aminomethyl)-2-((S)-2-aminopropanamido)-6-boronohexanoic acid To a solution of (2S,3R)-tert-butyl 3-((tert-butoxycarbonylamino)methyl)-2-((S)-2-(tert-butoxycarbonylamino)propanamido)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 30, 191 mg, 0.310 mmol) in DCM (4 mL) was added a solution of HBr (33 wt% in AcOH, 0.75 mL, 4.6 mmol) and the reaction was stirred at room temperature for 1.5 h. The reaction was diluted with Et2O (5 mL) and concentrated. This process was repeated two more times. The resulting residue was dissolved in 1 M aq. HCl (7 mL) and Et2O (7 mL). Phenylboronic acid (114 mg, 0.940 mmol) was added and the clear biphasic solution was stirred for 2 h at room temperature. The layers were separated and the aqueous layer was washed with Et2O (3 x 5 mL) and lyophilized. The resulting solid was dissolved in MeOH (1 mL) and purified by ion exchange chromatography (PoraPak Rxn CX 20 cc column). A 5% ammonia solution in MeOH (15 mL) was used to elute the desired product from the column. The resulting material was further purified by reverse phase chromatography (RediSep Rf Gold® C18, 0-100% acetonitrile in water) to give (2S,3R)-3-(aminomethyl)-2-((S)-2-aminopropanamido)-6-boronohexanoic acid (Example 14, 59 mg, 68% yield) as a white solid. 1 H NMR(300MHz,D2O)δ 0.67-0.87(2H,m),1.17-1.55(7H,m),2.39(1H,tq),2.74(1H,dd),3.12(1H,dd),3.79(1H,q),4.40(1H,d);m / z:(ES + ) [M+H] + =276.

[0193] Example 15: (2S,3R)-2-amino-3-(2-aminoethyl)-6-boronohexanoic acid dihydrochloride [ka]

[0194] Intermediate 31: (S,E)-tert-butyl 4-(3-ethoxy-3-oxoprop-1-enyl)-2,2-dimethyloxazolidine-3-carboxylate To a solution of tert-butyl (R)-4-formyl-2,2-dimethyloxazolidine-3-carboxylate (6.00 g, 26.2 mmol) in toluene (220 mL) at 0° C. was added methyl(triphenylphosphoranylidene)acetate (9.62 g, 28.8 mmol). After the addition, the reaction was allowed to warm to room temperature and stirred for 40 h. The reaction mixture was concentrated and the resulting residue was diluted with Et2O (50 mL). The solids were removed by filtration and washed with Et2O (20 mL). The filtrate was concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (S,E)-tert-butyl 4-(3-ethoxy-3-oxoprop-1-enyl)-2,2-dimethyloxazolidine-3-carboxylate (Intermediate 31, 5.74 g, 77% yield) as a mixture of rotamers. 1 H NMR(300MHz,CDCl3)δ 1.37-1.50(9H,m),1.51-1.57(3H,m),1.63(3H,br m / z:(ES + ) [M+H] + =286.

[0195] Intermediate 32: (S)-tert-butyl 4-((S)-1-ethoxy-1-oxohex-4-en-3-yl)-2,2-dimethyloxazolidine-3-carboxylate A three-neck flask was dried under N2. Copper(I) iodide (23.4 g, 123 mmol) was charged and the solid was diluted with THF (100 mL). The suspension was cooled to 5° C. and a solution of prop-1-en-1-ylmagnesium bromide (0.5 M in THF, 491 mL, 245 mmol) was added dropwise via an addition funnel under an atmosphere of N2. The mixture was stirred for 30 min at 5° C. and then cooled to −78° C. After stirring for 10 min at −78° C., trimethylsilyl chloride (15.68 mL, 122.7 mmol) was added, followed by a solution of (S,E)-tert-butyl 4-(3-ethoxy-3-oxoprop-1-enyl)-2,2-dimethyloxazolidine-3-carboxylate (Intermediate 31, 7.00 g, 24.5 mmol) in THF (20 mL). After addition, the reaction was stirred at -78°C for 30 min and then warmed to -30°C to -20°C with stirring for an additional 30 min. The reaction was carefully quenched with concentrated aq. NH4OH:saturated aq. NH4Cl (1:9, 200 mL) at -20°C. The crude mixture was warmed to room temperature and the solids were removed by vacuum filtration. The biphasic filtrate was separated and the aqueous layer was extracted with EtOAc (3 x 100 mL). The combined organics were dried over Na2SO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (S)-tert-butyl 4-((S)-1-ethoxy-1-oxohex-4-en-3-yl)-2,2-dimethyloxazolidine-3-carboxylate (Intermediate 32, 6.80 g, 85% yield) as a mixture of rotamers and E / Z olefins. 1 H NMR(300MHz,CDCl3)δ 1.40-1.52(12H,m),1.54-1.75(6H,m),2.14-2.36(1H,m),2.42-2.65(1H,m),3.29-3.5 5(1H,m),3.63(3H,m),3.73-4.01(3H,m),5.10-5.37(1H,m),5.46-5.70(1H,m);m / z:(ES + ) [M+H] + =328.

[0196] Intermediate 33: (S)-tert-butyl 4-((S)-1-hydroxyhex-4-en-3-yl)-2,2-dimethyloxazolidine-3-carboxylate (S)-tert-Butyl 4-((S)-1-ethoxy-1-oxohex-4-en-3-yl)-2,2-dimethyloxazolidine-3-carboxylate (Intermediate 32, 3.50 g, 10.7 mmol) was dissolved in anhydrous THF (18 mL) and the solution was cooled to 0° C. under an atmosphere of N2. To the reaction was added a solution of LAH (2 M in THF, 5.34 mL, 10.7 mmol) dropwise and the reaction mixture was stirred at 0° C. for 1 h. The reaction was carefully quenched at 0° C. with water (0.4 mL), 15% aq. NaOH (0.4 mL), and water (1.2 mL). The resulting suspension was allowed to warm to room temperature and stirred for 10 min. Na2SO4 (5 g) was added, the suspension was filtered, and the solid cake was washed with EtOAc (50 mL). The filtrate was concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (S)-tert-butyl 4-((S)-1-hydroxyhex-4-en-3-yl)-2,2-dimethyloxazolidine-3-carboxylate (Intermediate 33, 3.10 g, 97% yield) as a mixture of rotamers and E / Z olefins. 1 H NMR(300MHz,CDCl3)δ 1.43-1.52(14H,m),1.54-1.72(6H,m),1.73-1.88(1H,m),2.48-3.17(1H,m),3.5 0-3.73(2H,m),3.75-4.01(3H,m),5.12-5.38(1H,m),5.43-5.77(1H,m);m / z:(ES + ) [M+H] + =300.

[0197] Intermediate 34: (S)-tert-butyl 2,2-dimethyl-4-((S)-1-(methylsulfonyloxy)hex-4-en-3-yl)oxazolidine-3-carboxylate To a solution of (S)-tert-butyl 4-((S)-1-hydroxyhex-4-en-3-yl)-2,2-dimethyloxazolidine-3-carboxylate (Intermediate 33, 3.00 g, 10.0 mmol) in DCM (25 mL) at 0° C., triethylamine (1.96 mL, 14.0 mmol) and methanesulfonic anhydride (2.27 g, 13.0 mmol) were added successively. The reaction was allowed to warm to room temperature and stirred for 1 h. The crude reaction mixture was diluted with DCM (25 ml) and washed with 1 M aq. HCl (10 mL) and saturated NaHCO3 (5 mL). The organics were dried over Na2SO4, filtered, and concentrated to dryness to give (S)-tert-butyl 2,2-dimethyl-4-((S)-1-(methylsulfonyloxy)hex-4-en-3-yl)oxazolidine-3-carboxylate (Intermediate 34) as a mixture of rotamers and E / Z olefins, which was used without further purification. 1 H NMR(300MHz,CDCl3)δ 1.39-1.51(12H,m),1.53-1.64(4H,m),1.66-1.77(3H,m),1.89-2.12(1H,m),2.97(3H,s),3.07-3.20(1H, m),3.74-4.00(3H,m),4.03-4.17(1H,m),4.22-4.35(1H,m),5.05-5.27(1H,m),5.54-5.84(m,1H);m / z:(ES + ) [M+H] + =378.

[0198] Intermediate 35: (S)-tert-butyl 4-((S)-1-(bis(tert-butoxycarbonyl)amino)hex-4-en-3-yl)-2,2-dimethyloxazolidine-3-carboxylate To a solution of di-tert-butyl iminodicarboxylate (2.319 g, 10.68 mmol) in DMF (30 mL) at 0° C. was added sodium hydride (60 wt % in oil, 427 mg, 10.68 mmol) and the suspension was stirred at 0° C. for 20 min and then warmed to room temperature with stirring for an additional 10 min. A solution of (S)-tert-butyl 2,2-dimethyl-4-((S)-1-(methylsulfonyloxy)hex-4-en-3-yl)oxazolidine-3-carboxylate (Intermediate 34, 2.60 g, 6.89 mmol) in DMF (3 mL) was added and the reaction was heated to 95° C. for 3 h under an atmosphere of N2. The reaction mixture was cooled to room temperature and concentrated. The resulting residue was diluted with water (10 mL) and EtOAc (20 mL) and the layers were separated. The organic phase was dried over Na2SO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexane / EtOAc) to give (S)-tert-butyl 4-((S)-1-(bis(tert-butoxycarbonyl)amino)hex-4-en-3-yl)-2,2-dimethyloxazolidine-3-carboxylate (Intermediate 35, 2.60 g, 76% yield). 1 H NMR(300MHz,CDCl3)δ 1.36-1.52(30H,m),1.53-1.95(8H,m),2.26-2.97(1H,m),3.28-3.44(1H,m),3.4 8-3.66(1H,m),3.70-4.00(3H,m),5.14-5.29(1H,m),5.40-5.83(1H,m);m / z:(ES + )[M+Na] + =521.

[0199] Intermediate 36: tert-Butyl (tert-butoxycarbonyl) ((S)-3-((S)-1-((tert-butoxycarbonyl)amino)-2-hydroxyethyl)hex-4-en-1-yl)carbamate To a solution of (S)-tert-butyl 4-((S)-1-(bis(tert-butoxycarbonyl)amino)hex-4-en-3-yl)-2,2-dimethyloxazolidine-3-carboxylate (Intermediate 35, 1.50 g, 3.01 mmol) in acetonitrile (30 mL) at room temperature, cerium(III) chloride heptahydrate (3.36 g, 9.02 mmol) and oxalic acid (0.027 g, 0.30 mmol) were added successively. The resulting suspension was stirred at room temperature for 2 h. The suspension was filtered and the solid was washed with EtOAc. The filtrate was concentrated, then diluted with EtOAc (50 mL) and washed with water (20 mL) and brine (10 mL). The organic layer was dried over Na2SO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give tert-butyl (tert-butoxycarbonyl) ((S)-3-((S)-1-((tert-butoxycarbonyl)amino)-2-hydroxyethyl)hex-4-en-1-yl)carbamate (Intermediate 36, 830 mg, 60% yield). 1 H NMR(300MHz,CDCl3)δ 1.43(9H,s),1.49(18H,s),1.56-1.85(5H,m),2.17-2.77(1H,m),3.34-3.7 2(5H,m),4.52-4.76(1H,m),5.13-5.35(1H,m),5.47-5.78(1H,m);m / z:(ES + ) [M+H] + =459.

[0200] Intermediate 37: (2S,3S)-3-(2-(bis(tert-butoxycarbonyl)amino)ethyl)-2-(tert-butoxycarbonylamino)hex-4-enoic acid tert-Butyl (tert-butoxycarbonyl)((S)-3-((S)-1-((tert-butoxycarbonyl)amino)-2-hydroxyethyl)hex-4-en-1-yl)carbamate (Intermediate 36, 400 mg, 0.87 mmol) was dissolved in acetone (5 mL) and cooled to −20 °C under an atmosphere of N2. Jones reagent (2.37 M in aq H2SO4, 1.14 mL, 3.05 mmol) was slowly added and the solution was stirred at −20 to −10 °C for 5 h. The reaction mixture was concentrated and the residue was partitioned between water (10 mL) and EtOAc (10 mL). The aqueous phase was extracted with EtOAc (3 × 10 mL). The combined organics were dried over Na2SO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give impure (2S,3S)-3-(2-(bis(tert-butoxycarbonyl)amino)ethyl)-2-(tert-butoxycarbonylamino)hex-4-enoic acid (Intermediate 37, 200 mg, 48% yield). m / z: (ES + ) [M+H] + =471.

[0201] Intermediate 38: (2S,3S)-tert-butyl 3-(2-(bis(tert-butoxycarbonyl)amino)ethyl)-2-(tert-butoxycarbonylamino)hex-4-enoate To a solution of (2S,3S)-3-(2-(bis(tert-butoxycarbonyl)amino)ethyl)-2-(tert-butoxycarbonylamino)hex-4-enoic acid (Intermediate 37, 250 mg, 0.53 mmol) in DCM (5 mL) was added 2-tert-butyl-1,3-diisopropylisourea (0.42 mL, 1.9 mmol) and the reaction was stirred at room temperature under an atmosphere of N2 for 16 h. The reaction suspension was filtered to remove insoluble solids. To the filtrate was added 2-tert-butyl-1,3-diisopropylisourea (0.05 mL, 0.2 mmol) and the reaction was stirred at room temperature for an additional 48 h. The crude mixture was concentrated to dryness and directly purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 3-(2-(bis(tert-butoxycarbonyl)amino)ethyl)-2-(tert-butoxycarbonylamino)hex-4-enoate (Intermediate 38, 120 mg, 43% yield) as a sticky oil. 1 H NMR(300MHz,CDCl3)δ 1.33-1.57(37H,m),1.60-1.68(3H,m),1.71-1.90(1H,m),2.45-3.06(1H,m),3.37-3.66 (2H,m),4.20-4.28(1H,m),4.90-5.08(1H,m),5.18(1H,td),5.44-5.87(1H,m);m / z:(ES + )[M+Na] + =551.

[0202] Intermediate 39: (2S,3R)-tert-butyl 3-(2-(bis(tert-butoxycarbonyl)amino)ethyl)-2-(tert-butoxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate Bis(1,5-cyclooctadiene)diiridium(I) dichloride (15 mg, 0.022 mmol) and bis(diphenylphosphino)methane (17 mg, 0.046 mmol) were placed in an oven-dried round-bottom flask. The flask was sealed and purged with N2. The solid was dissolved in DCM (2.6 mL) and to this solution was slowly added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.21 mL, 1.4 mmol). The reaction was stirred at room temperature for 10 min. To the reaction was added (2S,3S)-tert-butyl 3-(2-(bis(tert-butoxycarbonyl)amino)ethyl)-2-(tert-butoxycarbonylamino)hex-4-enoate (Intermediate 38, 300 mg, 0.57 mmol) as a solution in DCM (2 mL) and the reaction was stirred at room temperature for 24 h. The reaction mixture was concentrated to dryness and purified directly by silica gel chromatography (hexanes / EtOAc) to give (2S,3R)-tert-butyl 3-(2-(bis(tert-butoxycarbonyl)amino)ethyl)-2-(tert-butoxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 39, 100 mg, 27% yield) as a colorless oil. 1 H NMR(300MHz,CDCl3)δ 0.73(2H,t),1.22(12H,s),1.43(12H,s),1.46-1.74(30H,m),1.80-1.90(1H,br d),3.42-3.77(2H,m),4.28(1H,br dd),5.03(1H,br d);m / z:(ES + )[M+Na] + =679.

[0203] Example 15: (2S,3R)-2-amino-3-(2-aminoethyl)-6-boronohexanoic acid dihydrochloride (2S,3R)-tert-Butyl 3-(2-(bis(tert-butoxycarbonyl)amino)ethyl)-2-(tert-butoxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 39, 230 mg, 0.35 mmol) was dissolved in HCl (4M in dioxane, 1.75 mL, 7.01 mmol) and the reaction was stirred at room temperature for 30 min under an atmosphere of N2. The reaction was heated to 60° C. and stirred for 1 h. The reaction was cooled to room temperature and diluted with 1 M aq. HCl (1 mL). Phenylboronic acid (214 mg, 1.75 mmol) was added and the reaction was heated to 60° C. for 1 h. The reaction mixture was cooled to room temperature and the volatiles were removed under vacuum. The crude solution was diluted with water (5 mL) and washed with EtOAc (4×3 mL). The aqueous phase was lyophilized to give (2S,3R)-2-amino-3-(2-aminoethyl)-6-boronohexanoic acid dihydrochloride (Example 15, 80 mg, 78% yield) as a dry film. 1 H NMR(300MHz,D2O)δ 0.81(2H,br t),1.35-1.55(4H,m),1.72-1.91(2H,m),2.06-2.30(1H,m),3.05-3.23(2H,m),4.07(1H,d);m / z:(ES + ) [M+H] + =219.

[0204] Example 16: (2S,3S)-2-Amino-6-borono-3-carbamoylhexanoic acid [ka]

[0205] Intermediate 40: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-carbamoylhex-5-enoate To a solution of 2-((S)-1-(benzyloxycarbonylamino)-2-tert-butoxy-2-oxoethyl)pent-4-enoic acid (Intermediate 3, 270 mg, 0.74 mmol) in DMF (3 mL) was added HATU (311 mg, 0.818 mmol), ammonium chloride (159 mg, 2.97 mmol), and N,N-diisopropylethylamine (0.78 mL, 4.5 mmol) and the reaction was stirred at room temperature for 15 h. The mixture was diluted with DCM and saturated aqueous ammonium chloride. The layers were separated and the aqueous layer was extracted with DCM. The combined organics were dried over Na2SO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give the pure diastereomers (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-carbamoylhex-5-enoate (Intermediate 40, 148 mg, 55% yield) and (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-carbamoylhex-5-enoate (86 mg, 32% yield). The stereochemistry of the major diastereomer was assigned by analogy to the previous analog. 1 H NMR(500MHz,CDCl3)δ 1.39(9H,s),2.26-2.47(2H,m),2.78-3.00(1H,m),4.19-4.43(1H,m),5.01-5.16(4H,m),5.71-5 .81(1H,m),5.82-5.87(1H,m),5.96-6.05(1H,m),6.13-6.21(1H,m),7.25-7.37(5H,m);m / z:(ES + ) [M+H] + =363.

[0206] Intermediate 41: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-carbamoyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate Bis(1,5-cyclooctadiene)diiridium(I) dichloride (15 mg, 0.022 mmol) and bis(diphenylphosphino)ethane (18 mg, 0.045 mmol) were placed in an oven-dried round-bottom flask. The flask was sealed and purged with N2. The solid was dissolved in DCM (1.5 mL) and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (67 μL, 0.46 mmol) was slowly added to the solution. The reaction was stirred at room temperature for 10 minutes. To the reaction was added (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-carbamoylhex-5-enoate (Intermediate 40, 84 mg, 0.23 mmol) as a solution in DCM (1 mL) and the reaction was stirred at room temperature for 15 hours. The reaction mixture was cooled to 0° C. and quenched with MeOH (2 mL) and water (10 mL). The layers were separated and the aqueous layer was extracted with DCM (2×10 mL). The combined organics were dried over MgSO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-carbamoyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 41, 73 mg, 64% yield). 1 H NMR(400MHz,CDCl3)δ 0.72-0.82(2H,m),1.20(12H,s),1.34-1.41(9H,m),1.43-1.52(2H,m),1.53-1.62(1H,m),1.62-1.72(1H,m),2.68-2.93(1H, m / z:(ES + ) [M+H] + =491.

[0207] Example 16: (2S,3S)-2-Amino-6-borono-3-carbamoylhexanoic acid To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-carbamoyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 41, 73 mg, 0.15 mmol) in DCM (2 mL) was added a solution of HBr (33 wt% in AcOH, 0.5 mL, 2.8 mmol) and the reaction was stirred for 1 h at room temperature. The reaction was concentrated and the resulting residue was diluted with Et2O (2 mL) and 2 M aq. HCl (2 mL). Phenylboronic acid (36 mg, 0.30 mmol) was added and the clear biphasic solution was stirred for 15 h at room temperature. The layers were separated and the aqueous layer was washed with Et2O (3 x 10 mL) and lyophilized. The resulting solid was dissolved in MeOH (1 mL) and purified by ion exchange chromatography (PoraPak Rxn CX 20 cc column). The desired product was eluted from the column using a 5% ammonia solution in MeOH (15 mL) to give (2S,3S)-2-amino-6-borono-3-carbamoylhexanoic acid (Example 16, 31 mg, 96% yield) as a white solid. 1 H NMR(500MHz,D2O)δ 0.79(2H,td),1.44(2H,quin),1.53-1.61(1H,m),1.64-1.73(1H,m),2.87-3.00(1H,m),3.77(1H,d);m / z:(ES + ) [M+H] + =219.

[0208] Example 17: (2S,3S)-2-Amino-6-borono-3-(methylcarbamoyl)hexanoic acid [ka]

[0209] Intermediate 42: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(methylcarbamoyl)hex-5-enoate To a solution of 2-((S)-1-(benzyloxycarbonylamino)-2-tert-butoxy-2-oxoethyl)pent-4-enoic acid (Intermediate 3, 231 mg, 0.64 mmol) in DMF (3 mL) was added HATU (266 mg, 0.699 mmol), methylamine hydrochloride (172 mg, 2.54 mmol), and N,N-diisopropylethylamine (0.67 mL, 3.8 mmol) and the reaction was stirred at room temperature for 15 h. The mixture was diluted with DCM and saturated aqueous ammonium chloride. The layers were separated and the aqueous layer was extracted with DCM. The combined organics were dried over Na2SO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give the pure diastereomers (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(methylcarbamoyl)hex-5-enoate (Intermediate 42, 133 mg, 56% yield) and (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(methylcarbamoyl)hex-5-enoate (77 mg, 32% yield). The stereochemistry of the major diastereomer was assigned by analogy to the previous analog. 1 H NMR(500MHz,CDCl3)δ 1.37(9H,s),2.24-2.45(2H,m),2.71(3H,d),2.81(1H,td),4.19-4.41(1H,m),4.96-5.18( m / z:(ES + ) [M+H] + =377.

[0210] Intermediate 43: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(methylcarbamoyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate Bis(1,5-cyclooctadiene)diiridium(I) dichloride (8.1 mg, 0.012 mmol) and bis(diphenylphosphino)ethane (9.7 mg, 0.024 mmol) were placed in an oven-dried round-bottom flask. The flask was sealed and purged with N2. The solid was dissolved in DCM (1 mL) and to the solution was slowly added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (59 μL, 0.40 mmol). The reaction was stirred at room temperature for 10 min. To the reaction was added (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(methylcarbamoyl)hex-5-enoate (Intermediate 42, 76 mg, 0.20 mmol) as a solution in DCM (1.5 mL) and the reaction was stirred at room temperature for 15 h. The reaction mixture was cooled to 0° C. and quenched with MeOH (2 mL) and water (10 mL). The layers were separated and the aqueous layer was extracted with DCM (2×10 mL). The combined organics were dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(methylcarbamoyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 43, 70 mg, 69% yield). 1 H NMR(500MHz,CDCl3)δ 0.64-0.87(2H,m),1.20(13H,s),1.31-1.45(10H,m),1.49-1.60(1H,m),1.63-1.72(1H,m),2.60-2.77(4H,m),4.30(1H,br m / z:(ES + ) [M+H] + =505.

[0211] Example 17: (2S,3S)-2-Amino-6-borono-3-(methylcarbamoyl)hexanoic acid To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(methylcarbamoyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 43, 70 mg, 0.14 mmol) in DCM (2 mL) was added a solution of HBr (33 wt% in AcOH, 0.5 mL, 2.8 mmol) and the reaction was stirred for 1 h at room temperature. The reaction was concentrated and the resulting residue was diluted with Et2O (2 mL) and 2 M aq. HCl (2 mL). Phenylboronic acid (34 mg, 0.28 mmol) was added and the clear biphasic solution was stirred for 15 h at room temperature. The layers were separated and the aqueous layer was washed with Et2O (3 x 10 mL) and lyophilized. The resulting solid was dissolved in MeOH (1 mL) and purified by ion exchange chromatography (PoraPak Rxn CX 20 cc column). The desired product was eluted from the column using a 5% ammonia solution in MeOH (15 mL) to give (2S,3S)-2-amino-6-borono-3-(methylcarbamoyl)hexanoic acid (Example 17, 30 mg, 93% yield) as a white solid. 1 H NMR(500MHz,D2O)δ m / z:(ES + ) [M+H] + =233.

[0212] Example 18: (2S,3S)-2-Amino-3-(aminomethyl)-6-boronohexanoic acid dihydrochloride [ka]

[0213] Intermediate 44: (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((methylsulfonyloxy)methyl)hex-5-enoate To a solution of (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-(hydroxymethyl)hex-5-enoate (Intermediate 5, 1.00 g, 2.86 mmol) in DCM (20 mL) at 0° C. was added triethylamine (1.70 mL, 12.2 mmol) and methanesulfonyl chloride (0.60 mL, 7.7 mmol). The reaction was allowed to warm to room temperature and stirred for 90 min. The crude mixture was diluted with DCM (10 mL) and washed successively with saturated aqueous sodium bicarbonate, water, and brine (25 mL each). The organic layer was dried over MgSO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((methylsulfonyloxy)methyl)hex-5-enoate (Intermediate 44, 1.17 g, 96% yield) as a pale yellow oil. 1 H NMR(300MHz,CDCl3)δ 1.46(9H,s),1.94-2.11(1H,m),2.18-2.32(1H,m),2.34-2.53(1H,m),2.97(3H,s),4.12-4.24(2H,m),4.45(1H,br m / z:(ES + )[M+NH4] + =445.

[0214] Intermediate 45: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((1,3-dioxoisoindolin-2-yl)methyl)hex-5-enoate Potassium phthalimide (0.558 g, 3.01 mmol) and potassium iodide (0.227 g, 1.37 mmol) were placed in an oven-dried flask under an atmosphere of N2. (2S,3R)-tert-butyl 2-(benzyloxycarbonylamino)-3-((methylsulfonyloxy)methyl)hex-5-enoate (Intermediate 44, 1.17 g, 2.74 mmol) was added as a solution in DMF (15 mL) and the reaction was heated to 95 °C for 3 h. The reaction mixture was cooled to room temperature and diluted with water (30 mL). The layers were separated and the aq. layer was extracted with Et2O (3 x 20 mL). The combined organics were dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((1,3-dioxoisoindolin-2-yl)methyl)hex-5-enoate (Intermediate 45, 0.725 g, 55% yield) as a colorless oil. 1 H NMR(300MHz,CDCl3)δ 1.20(9H,s),2.04-2.26(2H,m),2.69(1H,pentet),3.61(2H,d),4.47(1H,br m / z:(ES + )[M+NH4] + =496.

[0215] Intermediate 46: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((1,3-dioxoisoindolin-2-yl)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate Bis(1,5-cyclooctadiene)diiridium(I) dichloride (31 mg, 0.046 mmol) and bis(diphenylphosphino)methane (35 mg, 0.090 mmol) were placed in an oven-dried round-bottom flask. The flask was sealed and purged with N2. The solid was dissolved in DCM (5 mL) and to the solution was slowly added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.50 mL, 3.5 mmol). The reaction was stirred at room temperature for 10 min. To the reaction was added (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((1,3-dioxoisoindolin-2-yl)methyl)hex-5-enoate (Intermediate 45, 725 mg, 1.52 mmol) as a solution in DCM (4 mL) and the reaction was stirred at room temperature for 15 h. The reaction mixture was cooled to 0° C. and quenched with MeOH (2 mL) and water (10 mL). The layers were separated and the aqueous layer was extracted with DCM (2×10 mL). The combined organics were dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to afford (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((1,3-dioxoisoindolin-2-yl)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 46, 612 mg, 67% yield) as a glassy colorless residue. 1 H NMR(300MHz,CDCl3)δ 0.79(2H,br t),1.19(12H,s),1.21(9H,s),1.25-1.54(3H,m),1.59-1.77(1H,m),2.51-2.66(1H,m),3.49-3.67(2H,m),4.44(1H,br m / z:(ES + )[M+NH4] + =624.

[0216] Example 18: (2S,3S)-2-Amino-3-(aminomethyl)-6-boronohexanoic acid dihydrochloride (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((1,3-dioxoisoindolin-2-yl)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 46, 315 mg, 0.520 mmol) was dissolved in 6M aq. HCl (5 mL) and the solution was heated to 100° C. for 16 h. The reaction was cooled to room temperature, diluted with water (10 mL) and washed with ether (3×10 mL). The aqueous layer was lyophilized and purified by reverse phase chromatography (RediSep Rf Gold® C18Aq, 0-100% MeCN in water) to give (2S,3S)-2-amino-3-(aminomethyl)-6-boronohexanoic acid dihydrochloride (Example 18, 94 mg, 65% yield) as a yellow solid. 1 H NMR(300MHz,D2O)δ 0.73-0.91(2H,m),1.34-1.64(4H,m),2.29-2.45(1H,m),3.27(2H,qd),4.16(1H,d);m / z:(ES + ) [M-H2O+H] + =187.

[0217] Example 19: (2S,3S)-2-amino-3-(((S)-2-amino-3-methylbutanamido)methyl)-6-boronohexanoic acid [ka]

[0218] Intermediate 47: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((N-(tert-butoxycarbonyl)-2-(trimethylsilyl)ethylsulfonamido)methyl)hex-5-enoate (2S,3R)-tert-Butyl 2-(benzyloxycarbonylamino)-3-(hydroxymethyl)hex-5-enoate (Intermediate 5, 747 mg, 2.14 mmol) and tert-butyl ((2-(trimethylsilyl)ethyl)sulfonyl)carbamate (602 mg, 2.14 mmol) were dissolved in THF (10 mL) and cooled to 0° C. Triphenylphosphine (842 mg, 3.21 mmol) and DIAD (0.85 mL, 4.4 mmol) were added and the reaction was stirred for 16 h with slow warming to room temperature. The reaction was quenched with saturated aqueous sodium bicarbonate (20 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (2×15 mL). The combined organics were dried over MgSO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((N-(tert-butoxycarbonyl)-2-(trimethylsilyl)ethylsulfonamido)methyl)hex-5-enoate (Intermediate 47, 860 mg, 66% yield). 1 H NMR(500MHz,CDCl3)0.04(9H,s),0.91-1.01(2H,m),1.46(9H,s),1.50(9H,s),2.04 -2.13(2H,m),2.41-2.65(1H,m),3.33-3.47(2H,m),3.58-3.81(2H,m),4.40(1H,br d),4.96-5.19(4H,m),5.66(1H,br d),5.72-5.96(1H,m),7.25-7.41(5H,m);m / z:(ES + )[M+NH4] + =630.

[0219] Intermediate 48: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)hex-5-enoate To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((N-(tert-butoxycarbonyl)-2-(trimethylsilyl)ethylsulfonamido)methyl)hex-5-enoate (Intermediate 47, 1.23 g, 2.01 mmol) in THF (6 mL) was added a solution of TBAF (1 M in THF, 6.0 mL, 6.0 mmol) and the reaction was stirred at room temperature for 30 min. The reaction was diluted with Et2O (30 mL) followed by washing with water (3 x 15 mL). The organic layer was dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to afford (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)hex-5-enoate (Intermediate 48, 834 mg, 93% yield) as a pale yellow oil. 1 H NMR(500MHz,CDCl3)δ 1.41(9H,s),1.45(9H,s),1.90-1.99(1H,m),2.06-2.16(1H,m),2.17-2.30(1H,m),2.92-3.14(1H,m),3.14-3.27(1H,m),4.36(1H,br m / z:(ES + ) [M+H] + =449.

[0220] Intermediate 49: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate Bis(1,5-cyclooctadiene)diiridium(I) dichloride (48 mg, 0.071 mmol) and bis(diphenylphosphino)methane (55 mg, 0.14 mmol) were placed in an oven-dried round-bottom flask. The flask was sealed and purged with N2. The solid was dissolved in DCM (7 mL) and to the solution was slowly added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.76 mL, 5.2 mmol). The reaction was stirred at room temperature for 10 min. To the reaction was added (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)hex-5-enoate (Intermediate 48, 1.071 g, 2.39 mmol) as a solution in DCM (6 mL) and the reaction was stirred at room temperature for 15 h. The reaction mixture was cooled to 0° C. and quenched with MeOH (2 mL) and water (15 mL). The layers were separated and the aqueous layer was extracted with DCM (2×10 mL). The combined organics were dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 49, 1.01 g, 73% yield) as a pale yellow gum. 1 H NMR(500MHz,CDCl3)δ 0.75(2H,br t),1.20(12H,s),1.30-1.38(2H,m),1.40(9H,s),1.43(9H,s),1.46-1.51(2H,m),2.09(1H,br m / z:(ES + ) [M+H] + =577.

[0221] Intermediate 50: (2S,3S)-tert-butyl 3-(aminomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 49, 773 mg, 1.34 mmol) in dioxane (3.5 mL) was added a solution of HCl (4 M in dioxane, 3.35 mL, 13.4 mmol) at 0° C. The reaction was stirred for 2 h with gradual warming to room temperature. The solution was concentrated to dryness to give (2S,3S)-tert-butyl 3-(aminomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 50, 639 mg, 100% yield) as an off-white solid, which was used without further purification. m / z: (ES + ) [M+H] + =476.

[0222] Intermediate 51: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)-3-methylbutanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of Boc-Val-OH (220 mg, 1.01 mmol) in DMF (4 mL) was added HATU (385 mg, 1.01 mmol) and the reaction was stirred at room temperature for 10 min. To the reaction was then added (2S,3S)-tert-butyl 3-(aminomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 50, 438 mg, 0.919 mmol) as a solution in DMF (6 mL). N,N-Diisopropylethylamine (0.80 mL, 4.6 mmol) was added and the reaction was stirred at room temperature for 3 h. The reaction mixture was diluted with saturated aqueous NH4Cl and DCM and the layers were separated. The aqueous layer was extracted with DCM (3 x 20 mL). The combined organics were dried over Na2SO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)-3-methylbutanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 51, 450 mg, 72% yield) as a white foam. 1 H NMR(500MHz,CDCl3)δ 0.72(2H,br t),0.80-0.97(6H,m),1.13-1.35(13H,m),1.37-1.63(21H,m),1.95(1H,br s),2.07-2.17(1H,m),3.07-3.31(1H,m),3.34-3.54(1H,m),3.80-4.00(1H,m),4.14-4.28( m / z:(ES + ) [M+H] + =676.

[0223] Example 19: (2S,3S)-2-amino-3-(((S)-2-amino-3-methylbutanamido)methyl)-6-boronohexanoic acid To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)-3-methylbutanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 51, 450 mg, 0.67 mmol) in EtOAc (10 mL) was added Pd / C (10 wt%, 71 mg, 0.070 mmol). The flask was equipped with a balloon of H2 and the suspension was stirred at room temperature overnight. The reaction mixture was filtered through diatomaceous earth and rinsed with EtOAc and methanol. The filtrate was concentrated to dryness and the resulting residue was dissolved in HCl (4 M in dioxane, 10.0 mL, 40.0 mmol). The reaction was heated to 50° C. and stirred for 1.5 h. The reaction was cooled to room temperature and concentrated. The resulting residue was dissolved in 1M aq. HCl (15 ml) and Et2O (15 mL). Phenylboronic acid (155 mg, 1.27 mmol) was added and the reaction was stirred at room temperature for 4 hours. The reaction mixture was diluted with water and washed with Et2O. The aqueous layer was lyophilized and purified by ion exchange chromatography (PoraPak Rxn CX 20 cc column). The desired product was eluted from the column using 2.5M ammonia / methanol to give (2S,3S)-2-amino-3-(((S)-2-amino-3-methylbutanamido)methyl)-6-boronohexanoic acid (Example 19, 147 mg, 76% yield) as a white solid. 1 H NMR(500MHz,D2O)δ m / z:(ES + ) [M+H] + =304.

[0224] Example 20: (2S,3S)-2-amino-3-(((S)-2-aminopropanamido)methyl)-6-boronohexanoic acid [ka]

[0225] Intermediate 52: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)propanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of Boc-Ala-OH (279 mg, 1.48 mmol) in DMF (4 mL) was added HATU (561 mg, 1.48 mmol) and the reaction was stirred for 10 min at room temperature. To the reaction was then added (2S,3S)-tert-butyl 3-(aminomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 50, 639 mg, 1.34 mmol) as a solution in DMF (6 mL). N,N-Diisopropylethylamine (1.17 mL, 6.71 mmol) was added and the reaction was stirred for 3 h at room temperature. The reaction mixture was diluted with saturated aqueous NH4Cl and DCM and the layers were separated. The aqueous layer was extracted with DCM (3 x 30 mL). The combined organics were dried over Na2SO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)propanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 52, 662 mg, 76% yield) as a white solid. 1H NMR(500MHz,CDCl3)δ 0.65-0.78(2H,m),1.19(12H,s),1.32(3H,br d),1.37-1.55(22H,m),1.95-2.07(1H,m),3.10-3.27(1H,m),3.30-3.50(1H,m),3.87-4.45(2H,m),5.08(2H,br s),5.13-5.23(1H,m),5.76(1H,br s),6.52-6.80(1H,m),7.25-7.44(5H,m);m / z:(ES + ) [M+H] + =648.

[0226] Example 20: (2S,3S)-2-amino-3-(((S)-2-aminopropanamido)methyl)-6-boronohexanoic acid To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)propanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 52, 662 mg, 1.02 mmol) in Et2O (10 mL) was added Pd / C (10 wt%, 110 mg, 0.10 mmol). The flask was equipped with a balloon of H2 and the suspension was stirred at room temperature overnight. The reaction mixture was filtered through diatomaceous earth and rinsed with EtOAc and methanol. The filtrate was concentrated to dryness and the residue was dissolved in HCl (4 M in dioxane, 10.0 mL, 40.0 mmol) and the reaction was stirred at room temperature for 3.5 h. The reaction mixture was concentrated and the solid was triturated with Et2O. The solid was dissolved in 1M aq. HCl (15 ml) and Et2O (15 mL). Phenylboronic acid (245 mg, 2.01 mmol) was added and the reaction was stirred at room temperature overnight. The reaction mixture was diluted with water and washed with Et2O. The aqueous layer was lyophilized and purified by ion exchange chromatography (Silicycle SPE-R51230B-20X column). The desired product was eluted from the column using 2.5M ammonia / methanol to give (2S,3S)-2-amino-3-(((S)-2-aminopropanamido)methyl)-6-boronohexanoic acid (Example 20, 250 mg, 91% yield) as a white solid. 1 H NMR(500MHz,D2O)δ 0.68-0.79(2H,m),1.26(3H,br d),1.29-1.36(2H,m),1.37-1.49(2H,m),2.10-2.27(1H,m),3.16-3.37(2H,m),3.50-3.64(2H,m);m / z:(ES + ) [M+H] + =276.

[0227] Example 21: (2S,3S)-2-amino-3-(((S)-2-aminobutanamido)methyl)-6-boronohexanoic acid [ka]

[0228] Intermediate 53: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)butanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a suspension of HATU (220 mg, 0.58 mmol) and Boc-Abu-OH (230 mg, 1.13 mmol) in DCM (3 mL) was added N,N-diisopropylethylamine (0.49 mL, 2.8 mmol) and the reaction was stirred for 10 min at room temperature. To the suspension was added DMF (1 mL) and the reaction was stirred for an additional 5 min at room temperature. A solution of (2S,3S)-tert-butyl 3-(aminomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 50, 238 mg, 0.499 mmol) in DCM (2 mL) was added and the reaction was stirred overnight at room temperature. The reaction mixture was diluted with water and DCM and the layers were separated. The aqueous layer was extracted with DCM (2×20 mL). The combined organics were washed with saturated sodium chloride, dried over Na2SO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)butanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 53, 110 mg, 29% yield). 1H NMR(500MHz,CDCl3)δ 0.73(2H,br s),0.91(3H,br s),1.21(13H,br s),1.30-1.37(1H,m),1.39-1.43(9H,m),1.45(9H,br s),1.49-1.65(2H,m),1.86(1H,br s),2.00(1H,br s),2.14-2.69(1H,m),3.20(1H,br s),3.31-3.61(1H,m),3.99(1H,br s),4.13-4.34(1H,m),5.09(3H,br s),5.66-5.88(1H,m),6.46-6.72(1H,m),7.28-7.39(5H,m).

[0229] Example 21: (2S,3S)-2-amino-3-(((S)-2-aminobutanamido)methyl)-6-boronohexanoic acid To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)butanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 53, 107 mg, 0.162 mmol) in ethyl acetate (5 mL) was added Pd / C (10 wt%, 43 mg, 0.040 mmol). The flask was equipped with a balloon of H2 and the suspension was stirred at room temperature overnight. The reaction mixture was filtered through diatomaceous earth and rinsed with EtOAc and methanol. The filtrate was concentrated and the resulting residue was dissolved in DCM (1 mL) and trifluoroacetic acid (3 mL) and the reaction was stirred at room temperature overnight. The reaction was concentrated and the residue was dissolved in 1 M aq. HCl (2 mL) and Et2O (2 mL). Phenylboronic acid (38 mg, 0.31 mmol) was added and the reaction was stirred at room temperature for 3 hours. The reaction mixture was diluted with water and washed with Et2O. The aqueous layer was lyophilized and purified by ion exchange chromatography (PoraPak Rxn CX 20 cc column). The desired product was eluted from the column using a 5% solution of ammonia in methanol to give (2S,3S)-2-amino-3-(((S)-2-aminobutanamido)methyl)-6-boronohexanoic acid (Example 21, 40 mg, 89% yield) as a white solid. 1 H NMR(500MHz,D2O)δ 0.74(2H,td),0.85(3H,br m / z:(ES + ) [M+H] + =290.

[0230] Example 22: (2S,3S)-2-amino-3-(((2S,3S)-2-amino-3-methylpentanamido)methyl)-6-boronohexanoic acid [ka]

[0231] Intermediate 54: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((2S,3S)-2-(tert-butoxycarbonylamino)-3-methylpentanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a suspension of HATU (365 mg, 0.960 mmol) and Boc-Ile-OH (462 mg, 2.00 mmol) in DCM (3 mL) and DMF (3 mL) was added N,N-diisopropylethylamine (0.84 mL, 4.8 mmol) and the reaction was stirred at room temperature for 10 min. A solution of (2S,3S)-tert-butyl 3-(aminomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 50, 336 mg, 0.705 mmol) in DCM (3 mL) was added and the reaction was stirred at room temperature overnight. The reaction mixture was diluted with water and DCM and the layers were separated. The aqueous layer was extracted with DCM (2×20 mL). The combined organics were washed with saturated sodium bicarbonate, dried over Na2SO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((2S,3S)-2-(tert-butoxycarbonylamino)-3-methylpentanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 54, 260 mg, 47% yield). 1H NMR(500MHz,CDCl3)δ 0.73(2H,br t),0.83-0.97(6H,m),1.08(1H,br s),1.21(13H,br s),1.29-1.63(22H,m),1.82-1.92(1H,m),1.92-2.04(1H,m),3.18(1H,br s),3.43(1H,br d),3.96(1H,br s),4.21(1H,br d),5.09(3H,br s),5.58-5.80(1H,m),6.40-6.69(1H,m),7.29-7.40(5H,m).

[0232] Example 22: (2S,3S)-2-amino-3-(((2S,3S)-2-amino-3-methylpentanamido)methyl)-6-boronohexanoic acid To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((2S,3S)-2-(tert-butoxycarbonylamino)-3-methylpentanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 54, 256 mg, 0.371 mmol) in ethyl acetate (8 mL) was added Pd / C (10 wt%, 99 mg, 0.093 mmol). The flask was equipped with a balloon of H2 and the suspension was stirred at room temperature overnight. The reaction mixture was filtered through diatomaceous earth and rinsed with EtOAc and methanol. The filtrate was concentrated and the resulting residue was dissolved in DCM (2 mL) and trifluoroacetic acid (6 mL) and the reaction was stirred at room temperature for 3 h. The reaction was concentrated and the residue was dissolved in 1M aq. HCl (2 mL) and Et2O (5 mL). Phenylboronic acid (82 mg, 0.67 mmol) was added and the reaction was stirred overnight at room temperature. The reaction mixture was diluted with water and washed with Et2O. The aqueous layer was lyophilized and purified by ion exchange chromatography (PoraPak Rxn CX 20 cc column). The desired product was eluted from the column using a 5% solution of ammonia in methanol to give (2S,3S)-2-amino-3-(((2S,3S)-2-amino-3-methylpentanamido)methyl)-6-boronohexanoic acid (Example 22, 93 mg, 87% yield) as a white solid. 1 H NMR(500MHz,D2O)δ 0.68-0.78(2H,m),0.80-0.91(6H,m),1.07-1.18(1H,m),1.27-1.48(5H,m),1.69(1H,br d),2.14(1H,br d),3.21-3.36(3H,m),3.62(1H,br d);m / z:(ES + ) [M+H] + =318.

[0233] Example 23: (2S,3S)-2-amino-3-(((S)-2-amino-3,3-dimethylbutanamido)methyl)-6-boronohexanoic acid [ka]

[0234] Intermediate 55: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)-3,3-dimethylbutanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a suspension of HATU (472 mg, 1.24 mmol) and Boc-Tle-OH (550 mg, 2.4 mmol) in DCM (3 mL) and DMF (3 mL) was added N,N-diisopropylethylamine (1.08 mL, 6.20 mmol) and the reaction was stirred at room temperature for 10 min. A solution of (2S,3S)-tert-butyl 3-(aminomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 50, 434 mg, 0.911 mmol) in DCM (4.5 mL) was added and the reaction was stirred at room temperature overnight. The reaction mixture was diluted with water and DCM and the layers were separated. The aqueous layer was extracted with DCM (2×20 mL). The combined organics were washed with saturated sodium bicarbonate, dried over Na2SO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)-3,3-dimethylbutanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 55, 560 mg, 79% yield) as a colorless oil. 1H NMR(500MHz,CDCl3)δ 0.75(2H,br t),0.95-1.05(9H,m),1.18-1.25(13H,m),1.32-1.40(1H,m),1.42-1.45(9H,m),1 .46-1.51(9H,m),1.52-1.62(1H,m),1.64-1.73(1H,m),1.88-2.04(1H,m),3.08-3. 27(1H,m),3.39-3.56(1H,m),3.74-3.90(1H,m),4.18-4.30(1H,m),5.05-5.17(2H ,m),5.31(1H,s),5.47-5.80(1H,m),6.14-6.44(1H,m),7.30-7.40(5H,m);m / z:(ES + ) [M+H] + =690.

[0235] Example 23: (2S,3S)-2-amino-3-(((S)-2-amino-3,3-dimethylbutanamido)methyl)-6-boronohexanoic acid To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-(((S)-2-(tert-butoxycarbonylamino)-3,3-dimethylbutanamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 55, 359 mg, 0.521 mmol) in ethyl acetate (12 mL) was added Pd / C (10 wt%, 138 mg, 0.130 mmol). The flask was equipped with a balloon of H2 and the suspension was stirred at room temperature overnight. The reaction mixture was filtered through diatomaceous earth and rinsed with EtOAc and methanol. The filtrate was concentrated and the resulting residue was dissolved in DCM (3 mL) and trifluoroacetic acid (9 mL) and the reaction was stirred at room temperature for 3 h. The reaction was concentrated and the residue was dissolved in 1M aq. HCl (3 mL) and Et2O (5 mL). Phenylboronic acid (127 mg, 1.04 mmol) was added and the reaction was stirred overnight at room temperature. The reaction mixture was diluted with water and washed with Et2O. The aqueous layer was lyophilized and purified by ion exchange chromatography (PoraPak Rxn CX 20 cc column). The desired product was eluted from the column using a 5% solution of ammonia in methanol. The resulting material was further purified by reverse phase chromatography (RediSep Rf Gold® C18Aq, 0-10% acetonitrile in water) to give (2S,3S)-2-amino-3-(((S)-2-amino-3,3-dimethylbutanamido)methyl)-6-boronohexanoic acid (Example 23, 96 mg, 58% yield) as a white solid. 1 H NMR(500MHz,D2O w / TFA)δ m / z:(ES + ) [M+H] + =318.

[0236] Example 24: (2S,3S)-2-amino-3-((2-aminoacetamido)methyl)-6-boronohexanoic acid [ka]

[0237] Intermediate 56: (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((2-(tert-butoxycarbonylamino)acetamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a suspension of HATU (434 mg, 1.14 mmol) and Boc-Gly-OH (400 mg, 2.28 mmol) in DCM (3 mL) and DMF (3 mL) was added N,N-diisopropylethylamine (0.92 mL, 5.3 mmol) and the reaction was stirred at room temperature for 10 min. A solution of (2S,3S)-tert-butyl 3-(aminomethyl)-2-(benzyloxycarbonylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 50, 369 mg, 0.775 mmol) in DCM (3 mL) was added and the reaction was stirred at room temperature overnight. The reaction mixture was diluted with water and DCM and the layers were separated. The aqueous layer was extracted with DCM (2×20 mL). The combined organics were washed with saturated sodium chloride, dried over Na2SO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((2-(tert-butoxycarbonylamino)acetamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 56, 259 mg, 47% yield). 1H NMR(500MHz,CDCl3)δ 0.72(2H,br s),1.19(13H,br s),1.28-1.36(1H,m),1.36-1.45(18H,m),1.45-1.56(2H,m),2.03-2.13(1H,m),3.12(1H,br s),3.41(1H,br d),3.61-3.89(2H,m),4.16-4.38(1H,m),5.07(2H,br s),5.30-5.43(1H,m),5.95(1H,br s),6.73(1H,br s),7.22-7.36(5H,m).

[0238] Example 24: (2S,3S)-2-amino-3-((2-aminoacetamido)methyl)-6-boronohexanoic acid To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((2-(tert-butoxycarbonylamino)acetamido)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 56, 256 mg, 0.404 mmol) in ethyl acetate (8 mL) was added Pd / C (10 wt%, 107 mg, 0.101 mmol). The flask was equipped with a balloon of H2 and the suspension was stirred at room temperature overnight. The reaction mixture was filtered through diatomaceous earth and rinsed with EtOAc and methanol. The filtrate was concentrated and the resulting residue was dissolved in DCM (2 mL) and trifluoroacetic acid (6 mL) and the reaction was stirred at room temperature for 3 h. The reaction was concentrated and the residue was dissolved in 1 M aq. HCl (3 mL) and Et2O (5 mL). Phenylboronic acid (98 mg, 0.80 mmol) was added and the reaction was stirred overnight at room temperature. The reaction mixture was diluted with water and washed with Et2O. The aqueous layer was lyophilized and purified by ion exchange chromatography (PoraPak Rxn CX 20 cc column). The desired product was eluted from the column using a 5% solution of ammonia in methanol. The resulting material was further purified by reverse phase chromatography (RediSep Rf Gold® C18Aq, 0-5% acetonitrile in water) to give (2S,3S)-2-amino-3-((2-aminoacetamido)methyl)-6-boronohexanoic acid (Example 24, 20 mg, 19% yield) as a white solid. 1 H NMR(500MHz,D2O w / TFA)δ 0.53-0.74(2H,m),1.16-1.45(4H,m),2.17-2.31(1H,m),3.16-3.36(2H,m),3.57-3.71(2H,m),3.96(1H,d);m / z:(ES + ) [M+H] + =262.

[0239] Example 25: (2S,3S)-3-(aminomethyl)-2-[[(2S)-2-aminopropanoyl]amino]-6-borono-hexanoic acid [ka]

[0240] Intermediate 57: tert-Butyl (2S,3S)-2-amino-3-[(tert-butoxycarbonylamino)methyl]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of (2S,3S)-tert-butyl 2-(benzyloxycarbonylamino)-3-((tert-butoxycarbonylamino)methyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 49, 1.40 g, 2.43 mmol) in EtOAc (50 mL) was added Pd / C (10 wt%, 243 mg, 0.228 mmol). The flask was equipped with a balloon of H2 and the suspension was stirred at room temperature overnight. The reaction mixture was filtered through diatomaceous earth and rinsed with EtOAc. The filtrate was evaporated to dryness to give the crude material as a colorless oil. The crude material was subjected to chiral SFC [Chiral Pak IC column, 21×250 mm, 5 μm, temperature=40° C., mobile phase=15% isopropanol (with 0.2% NH4OH):CO2, flow rate=4 mL / min, outlet pressure=100 bar] to give tert-butyl (2S,3S)-2-amino-3-[(tert-butoxycarbonylamino)methyl]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 57, 855 mg, 80% yield, >98:2 dr) as a colorless oil. 1 H NMR(500MHz,CDCl3)δ 0.80(2H,t),1.19-1.33(14H,m),1.35-1.56(20H,m),1.61-1.85(2H,m),1.88-2.00(1H,m),3.10-3.31(2H,m),3.39(1H,d),5.25(1H,br s);m / z:(ES + ) [M+H] + =444.

[0241] Intermediate 58: tert-Butyl (2S,3S)-3-[(tert-butoxycarbonylamino)methyl]-2-[[(2S)-2-(tert-butoxycarbonylamino)propanoyl]amino]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of Boc-Ala-OH (70 mg, 0.37 mmol) in DMF (6 mL) was added HATU (142 mg, 0.373 mmol) and the reaction was stirred at room temperature for 10 min. To the reaction was then added tert-butyl (2S,3S)-2-amino-3-[(tert-butoxycarbonylamino)methyl]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 57, 150 mg, 0.34 mmol) as a solution in DMF (2 mL). N,N-Diisopropylethylamine (0.12 mL, 0.68 mmol) was added and the reaction was stirred overnight at room temperature. The reaction mixture was diluted with saturated aqueous NH4Cl and DCM and the layers were separated. The aqueous layer was extracted with DCM (3 x 20 mL). The combined organics were dried over Na2SO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give tert-butyl (2S,3S)-3-[(tert-butoxycarbonylamino)methyl]-2-[[(2S)-2-(tert-butoxycarbonylamino)propanoyl]amino]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 58, 125 mg, 60% yield) as a white solid. 1 H NMR(500MHz,CDCl3)δ 0.71-0.82(2H,m),1.16-1.36(14H,m),1.37-1.69(34H,m),2.14-2.28(1H,m),3.01-3.10(1H,m),3.19-3. 35(1H,m),4.21-4.36(1H,m),4.52-4.63(1H,m),4.66-4.80(1H,m),5.21-5.32(1H,m),7.13-7.25(1H,m).

[0242] Example 25: (2S,3S)-3-(aminomethyl)-2-[[(2S)-2-aminopropanoyl]amino]-6-borono-hexanoic acid tert-Butyl (2S,3S)-3-[(tert-butoxycarbonylamino)methyl]-2-[[(2S)-2-(tert-butoxycarbonylamino)propanoyl]amino]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 58, 125 mg, 0.204 mmol) was dissolved in HCl (4 M in dioxane, 7.0 mL, 28 mmol) and the reaction was heated to 50° C. and stirred for 2 h. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The resulting white solid was dissolved in 1 M aq. HCl (10 mL) and Et2O (10 mL). Phenylboronic acid (49 mg, 0.41 mmol) was added and the reaction was stirred for 1 h at room temperature. The reaction mixture was diluted with water and washed with Et2O. The aqueous layer was lyophilized and purified by ion exchange chromatography (PoraPak Rxn CX 20 cc column). The desired product was eluted from the column using 2.5M ammonia / methanol. The resulting material was further purified by reverse phase chromatography (RediSep Rf Gold® C18Aq, 0-20% acetonitrile in water) to give (2S,3S)-3-(aminomethyl)-2-[[(2S)-2-aminopropanoyl]amino]-6-borono-hexanoic acid (Example 25, 38 mg, 67% yield) as a white solid. 1 H NMR(500MHz,D2O)δ m / z:(ES + ) [M+H] + =276.

[0243] Example 26: (2S,3S)-3-(aminomethyl)-2-[[(2S)-2-amino-3-methyl-butanoyl]amino]-6-borono-hexanoic acid [ka]

[0244] Intermediate 59: tert-Butyl (2S,3S)-3-[(tert-butoxycarbonylamino)methyl]-2-[[(2S)-2-(tert-butoxycarbonylamino)-3-methyl-butanoyl]amino]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate To a solution of Boc-Val-OH (186 mg, 0.857 mmol) in DMF (10 mL) was added HATU (326 mg, 0.857 mmol) and the reaction was stirred at room temperature for 10 min. To the reaction was then added tert-butyl (2S,3S)-2-amino-3-[(tert-butoxycarbonylamino)methyl]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 57, 345 mg, 0.780 mmol) as a solution in DMF (5 mL). N,N-Diisopropylethylamine (0.27 mL, 1.6 mmol) was added and the reaction was stirred overnight at room temperature. The reaction mixture was diluted with saturated aqueous NH4Cl and DCM and the layers were separated. The aqueous layer was extracted with DCM (3 x 40 mL). The combined organics were dried over Na2SO4, filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (hexanes / EtOAc) to give tert-butyl (2S,3S)-3-[(tert-butoxycarbonylamino)methyl]-2-[[(2S)-2-(tert-butoxycarbonylamino)-3-methyl-butanoyl]amino]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 59, 422 mg, 84% yield) as a white solid. 1H NMR(500MHz,CDCl3)δ 0.77(2H,m),0.90-1.04(6H,m),1.13-1.36(14H,m),1.37-1.72(31H,m),2.12-2 .31(2H,m),2.94-3.08(1H,m),3.18-3.37(1H,m),4.00-4.11(1H,m),4.61(1H,br d),4.70(1H,br d),5.22(1H,m),7.08-7.20(1H,m).

[0245] Example 26: (2S,3S)-3-(aminomethyl)-2-[[(2S)-2-amino-3-methyl-butanoyl]amino]-6-borono-hexanoic acid tert-Butyl (2S,3S)-3-[(tert-butoxycarbonylamino)methyl]-2-[[(2S)-2-(tert-butoxycarbonylamino)-3-methyl-butanoyl]amino]-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanoate (Intermediate 59, 422, 0.658 mmol) was dissolved in HCl (4M in dioxane, 10.0 mL, 48.0 mmol) and the reaction was heated to 50° C. and stirred for 2 h. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The resulting white solid was dissolved in 1 M aq. HCl (15 mL) and Et2O (15 mL). Phenylboronic acid (160 mg, 1.32 mmol) was added and the reaction was stirred at room temperature for 1 h. The reaction mixture was diluted with water and washed with Et2O. The aqueous layer was lyophilized and purified by ion exchange chromatography (Silicycle SPE-R51230B-20X column). The desired product was eluted from the column using 2.5M ammonia / methanol. The resulting material was further purified by reverse phase chromatography (RediSep Rf Gold® C18Aq, 0-20% acetonitrile in water) to give (2S,3S)-3-(aminomethyl)-2-[[(2S)-2-amino-3-methyl-butanoyl]amino]-6-borono-hexanoic acid (Example 26, 162 mg, 81% yield) as a white solid. 1H NMR(500MHz,D2O)δ 0.76(2H,t),0.91(3H,d),0.95(3H,d),1.28-1.52(4H,m),1.99(1H,dq),2.18(1 m / z:(ES + ) [M+H] + =304.

[0246] Example 27: Biological activity of Examples 1 to 26 Recombinant Arginase 1 or Arginase 2 produced from E. coli was used to quantitate the inhibitory effects of Examples 1-26 on human Arginase 1 activity and Arginase 2 activity by measuring the formation of thioarginine-derived thiol groups. The thiol groups were detected with Ellman's reagent, 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB). DTNB reacts with thiols to produce mixed disulfides and 2-nitro-5-thiobenzoic acid (TNB), which is known as the anion (TNB 2- ) is quantified by absorbance at 412 nm.

[0247] The assay was performed in a clear 384-well plate (Greiner Cat. No. 781101). Using an Echo acoustic dispenser, various concentrations of Examples 1-26 in 300 nL of DMSO were dispensed into the assay plate, followed by immediate sealing and centrifugation of the plate. Two premixes were prepared from reagents that were thawed immediately prior to addition to the assay plate. Premix 1 contained human arginase 1 or human arginase 2 (final concentrations of 5 nM and 0.5 mM DTNB in ​​assay buffer), 45 mM HEPES pH 7.5, brij 35, 0.045% (w / v), and 100 μM MnCl2. Premix 2 contained freshly thawed 0.5 mM thioarginine in assay buffer. 15 microliters of premix 1 was dispensed into the assay plate containing Examples 1-9, which had been centrifuged and incubated at room temperature for 30 minutes, followed by 15 microliters of premix 2.

[0248] After centrifugation of the assay plate, the absorbance was read at 412 nm on a Pherastar multimode plate reader and data was collected at time point 0 (T0). The plate was incubated at room temperature for 60 minutes and then read again to collect data at time point 1 (T1). Data was derived by subtracting the A412 signal measured at T0 (time point 0) from the A412 signal measured at T1 (time point 1). The data was calculated using the following equation: Compound Effect % = 100 x [(X-Min) / (Max-Min)] The results were converted to % effect using the formula: where X represents the normalized value for compound based on minimum (vehicle) and maximum (reference compound) inhibition controls.

[0249] The concentrations of Examples 1 to 26 that inhibit the activity by 50% (i.e., IC 50 ) was calculated by plotting test compound concentration against % effect and fitting the data using the Genedata Screener Smart fit algorithm. The results of these assays are shown in Table 2.

[0250] [Table 5]

[0251] Example 28: Bioavailability Studies Example 14 is a prodrug form of Example 1. Examples 19-22 and 24-26 are prodrugs of Example 18. The following pharmacokinetic study was conducted to demonstrate the bioavailability of Example 18 from Example 19. For IV administration, Example 19 was formulated in 0.9 w / v% saline pH 4 (adjusted with 1M HCl). This formulation was administered at 2 mg / kg each to two male rats (170-250 g) via femoral catheter. Serial blood samples were taken from the jugular catheter at 0.033, 0.083, 0.167, 0.5, 1, 2, 4, 8, and 24 hours after administration. For PO administration, Example 19 was formulated in deionized water pH 4 (adjusted with 1M HCl) and administered at 5 mg / kg each to two male rats (170-250 g) via oral gavage. Serial blood samples were taken from the jugular catheter at 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, and 24 hours after administration. Plasma samples were generated from the blood using low-speed centrifugation. A single series of calibration standards, including Example 18 and Example 19, was prepared by spiking blank plasma. The samples and standards were extracted by precipitation with two volumes of acetonitrile and subsequent centrifugation. The results obtained were used to determine Cl (mL / min / kg), Vdss (L / kg), Cmax (μM), AUC (μMh), tmax (h), and %F for both Example 18 and Example 19. Absolute bioavailability was determined by comparing the AUC corrected for PO administration of Example 18 when administered as Example 19 to the AUC corrected for IV administration of Example 18 when administered as Example 18. Measured doses were used in this calculation instead of nominal doses, where appropriate. Similarly, the same procedure was repeated for Examples 14, 20-22, and 24-26. The results are shown in Tables 3-10. These results indicate that the incorporation of certain amino acid moieties as prodrugs can improve bioavailability.

[0252] [Table 6]

[0253]

Table 7

[0254]

Table 8

[0255]

Table 9

[0256]

Table 10

[0257]

Table 11

[0258]

Table 12

[0259]

Table 13

Claims

1. Formula (I): 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, During the ceremony, R 1 is hydrogen, -CH 3 and -(C=O)CH(R 1a ) N.H. 2 Selected from: R 1a is C 1 ~C 4 is alkyl; Y is -(CH 2 ) n - or -(C=O)-; n is an integer selected from 1 and 2; R 2 is hydrogen, -CH 3 and -(C=X)R 4 and R 3 is hydrogen or -CH 3 Is it; or R 2 and R 3 are linked together with the nitrogen to which they are attached to form a 6-membered heterocycle; X is NH or O; R 4 is -CH 3 or -[CH(R 4a ) ] m N.H. 2 and m is an integer selected from 0 or 1; and R 4a is hydrogen or C 1 ~C 6 is alkyl, A compound, or a pharma- ceutically acceptable salt thereof.

2. The compound of formula (I), or a pharma- ceutically acceptable salt thereof, has the formula (Ia): 【Chemistry 2】 The compound of claim 1 ,

3. The compound of formula (I), or a pharma- ceutically acceptable salt thereof, may be represented by formula (Ib): 【Chemistry 3】 The compound of claim 1 ,

4. Formula (II): 【Chemistry 4】 or a pharma- ceutically acceptable salt thereof, During the ceremony, R 11 is hydrogen, -CH 3 , and 【Chemistry 5】 wherein * indicates (S) stereochemistry; Y 1 is -(CH 2 ) p - or -(C=O)-; p is an integer selected from 1 and 2; R 11a is C 1 ~C 4 is alkyl; R 12 is hydrogen, -CH 3 , and -(C=X 1 ) R 14 and R 13 is hydrogen or -CH 3 Is it; or R 12 and R 13 are linked together with the nitrogen to which they are attached to form a 6-membered heterocycle; X 1 is NH or O; R 14 is -CH 3 or 【Chemistry 6】 where * indicates (S) stereochemistry; R 14a is C 1 ~C 4 is alkyl; and q is an integer selected from 0 and 1; A compound, or a pharma- ceutically acceptable salt thereof.

5. Formula (III): 【Chemistry 7】 or a pharma- ceutically acceptable salt thereof, During the ceremony, R 22 is hydrogen or 【Chemistry 8】 where * indicates (S) stereochemistry; and R 24a is C 1 ~C 4 is alkyl, A compound, or a pharma- ceutically acceptable salt thereof.

6. Formula (IV) 【Chemistry 9】 or a pharma- ceutically acceptable salt thereof, During the ceremony, R 11 teeth, 【Chemistry 10】 wherein * indicates (S) stereochemistry; and R 11a is C 1 ~C 4 is alkyl, A compound, or a pharma- ceutically acceptable salt thereof.

7. A compound selected from the following, or a pharma- ceutically acceptable salt thereof:

8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier, diluent, or excipient.

9. The pharmaceutical composition according to claim 8 for treating cancer.

10. A medicament for treating cancer, comprising a compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof.

11. The pharmaceutical composition according to claim 8 for treating respiratory inflammatory diseases.

12. A medicament for treating a respiratory inflammatory disease, comprising a compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof.

13. The pharmaceutical composition described in claim 11 or the pharmaceutical described in claim 12, wherein the respiratory inflammatory disease is selected from idiopathic pulmonary fibrosis, asthma, chronic obstructive pulmonary disease (COPD), and chemically induced pulmonary fibrosis.

Citation Information

Patent Citations

  • Arginase inhibitors and their therapeutic applications

    JP2013525364A

  • Arginase inhibitors and their use

    JP2014506253A

  • Compositions and Methods for Inhibiting Arginase Activity

    JP2018520352A

  • Compositions and methods for inhibiting arginase activity

    JP2018533582A